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ABSTRACT
Bladder cancer constitutes one of the most prevalent cancers and is among the
leading causes of cancer-related deaths in the United States. This work sought to better
characterize and understand the role of the proto-oncogene anterior gradient 2 (AGR2) in
bladder cancers. Immunohistochemical analysis of AGR2 expression in a range of
bladder cancer specimens indicated that the expression of AGR2 decreases with an
increase in the stage and grade of bladder cancers. The environmental carcinogens
arsenic and cadmium (Cd2+) have been implicated in various cancers. This laboratory has
demonstrated that arsenite (As3+) and Cd2+ can malignantly transform the bladder
epithelium cell line UROtsa. This study therefore sought to determine AGR2 expression
in six As3+ and seven Cd2+-transformed UROtsa cell lines in which real-time PCR and
western blotting data indicated that AGR2 expression was increased in several of the
transformed cell lines. Next AGR2 expression was evaluated in mouse heterotransplant
tumors arising from the injection of the previously transformed UROtsa cell lines in
athymic

nude

(Foxn1nu)

mice.

Results

from

real-time

PCR

analysis

and

immunohistochemistry on tumor samples demonstrated that AGR2 expression remained
increased in most of the Cd2+ heterotransplants but was significantly increased in only a
couple of the As3+ heterotransplants. UROtsa cells were further exposed to 2, 4, or 6 μM
As3+ or to 1, 2, or 4 μM Cd2+ for up to 72 hours and real-time PCR analysis was
performed to evaluate AGR2 expression. While AGR2 exhibited increased expression in

xiii

response to 48 hours As3+ exposure, expression was not induced to the same extent in
Cd2+ exposed UROtsa cells. Spheroids containing cancer initiating cells (CICs) were
generated from the transformed and the parent UROtsa cells and the expression of AGR2
was determined. The results obtained suggested that there was an increase in the
expression of AGR2 in all of the spheroids isolated from the As3+-transformed cells
whereas some of the spheroids isolated from the Cd2+-transformed cells expressed high
levels of AGR2 when compared to the spheroids isolated from the parent UROtsa cells.
This laboratory has also shown that As3+ and Cd2+ can cause malignant
transformation of a breast epithelial cell line, MCF-10A. Previous studies have shown
that the expression of AGR2 promotes breast tumorigenesis in mice. This gene is known
to play a role in promoting cellular transformation, tumor growth, and metastasis in
various cancers. This study was interested in determining the expression level of AGR2
in As3+ and Cd2+-transformed MCF-10A cells. Real-time PCR and Western analysis
indicated that the expression of AGR2 was significantly increased in the MCF-10A cells
transformed with As3+ when compared to the Cd2+-transformed cells. Exposure of the
parent MCF-10A cells to 4, 8, and 16 μM As3+ for 48 hours resulted in a significant
increase in the expression of AGR2 whereas exposure to Cd2+ did not increase the
expression of AGR2, suggesting that As3+ has the potential to induce AGR2 in MCF-10A
cells. In order to further investigate the effects of AGR2 expression on breast epithelial
cells, MCF-10A cells were transfected with the AGR2 gene. Overexpression of AGR2 in
the MCF-10A cells increased the ability of the cells to migrate faster in the wound
scratch assay when compared to the blank vector transfected cells. In addition, MTT and
scratch assays revealed increased growth and migration in the As3+-transformed cells

xiv

when compared to the parent MCF-10A cells and the Cd2+-transformed MCF-10A cells
further implicating AGR2 in enhancing cell growth and migration. Treatment of the
MCF-10A cells with the histone deacetylase inhibitor MS-275 and the demethylating
agent, 5-Aza-2'-deoxycytidine (5-AZC) increased the expression of AGR2 suggesting
that epigenetic modifications may be involved in regulating the expression of AGR2 in
MCF-10A cells. These data also suggest that the expression of AGR2 in the MCF-10A
cells may be regulated independently of the estrogen receptor status of the cells. Seeking
to gain a better understanding of the relationship between AGR2 expression and breast
cancer grade and stage, immunohistochemical staining was performed on a range of
breast cancer specimens. Results showed elevated AGR2 expression with increasing
grade of breast carcinoma. In conclusion, this study demonstrated the usefulness of
AGR2 expression as a biomarker for bladder and breast cancers, further characterized the
effect of AGR2 on the growth and migration of MCF-10A cells, and began to evaluate
possible mechanisms by which AGR2 expression may be induced.

xv

CHAPTER 1
INTRODUCTION
1.1 Bladder Cancer
Bladder cancer is the fourth most common type of cancer among men (Jacobs,
B.L., Lee, C.T., Montie 2010). Bladder cancer has previously been linked to cigarette
smoking as well as various chemicals and occupational exposures. Bladder cancer is also
of concern for women among whom it was estimated that 17,770 new cases would be
diagnosed in 2010 (Jemal et al. 2009). The variances between risk for men and women
are partially due to the fact that men were more likely to work in industrial jobs. One
study reported that the R198 cell line, a model of transitional cell carcinoma, produced
fewer tumors when transplanted into female or estrogen-treated male nude mice. This
suggests the possibility that androgens have a role in the formation of bladder cancers
which, in turn, may partially explain an increased prevalence of bladder cancers in men
over women (Reid et al. 1984).
Among the candidates for roles in bladder cancer is arsenic, which may be
involved in bladder carcinogenesis. In addition, most diagnosed bladder cancers are of a
papillary type, exhibiting low grade and stage. The concern is that most diagnosed
bladder cancers also have a high likelihood of recurrence (Johansson and Cohen 1997).
Bladder cancer risk has been associated with chemical and occupational carcinogen
exposure, cigarette smoking, certain chemotherapeutic drugs, urinary tract infections, and
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Schistosomiasis infections. Upon diagnosis, bladder cancer is classified as one of two
main subtypes: superficial (non-muscle invasive) or muscle invasive (Droller 1998).
1.1.1 Diagnosis of Bladder Cancer
There are still several challenges to diagnosing and treating bladder cancer,
among the most impactful are the need for better early detection methods. While most
newly-diagnosed cases are superficial, they also have a high rate of recurrence within five
years of initial diagnosis. This becomes more concerning as approximately 30% of
recurrent bladder cancers are likely to become muscle-invasive (Lamm 1998). Together
this stresses the challenge that bladder cancer is a high economic burden because of
expenses due to treatment, complications, and long-term screening for recurrence
(Bischoff and Clark 2009). Early detection is also a challenge because there are few
known early disease symptoms for bladder cancer. The few early symptoms that a subset
of patients experience include hematuria, frequent urination, and dysuria; all of these may
be indicators of other pathologies besides cancers (Droller 1998). Diagnosing bladder
cancer also relies upon cystoscopy, which is known to be unreliable in detecting flat
carcinoma in situ (CIS) lesions (Droller 1998). This is of great significance as it is the
CIS subtype that is most likely to progress to muscle-invasive disease.
1.1.2 Current Bladder Cancer Treatments
The treatment for most bladder cancers typically involves of transurethral
resection of the bladder tumor (TURBT) followed by intravesical therapy with Bacillus
Calmette-Guerin (BCG) (Jacobs, B.L., Lee, C.T., Montie 2010). For invasive bladder
cancers, radical cystectomy is recommended though around 50% of patients will exhibit
metastasis following this treatment (Bischoff and Clark 2009). More effective treatments
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are desired as up to 40% of BCG treated cancers exhibit recurrence with a second BCG
treatment providing a 35% chance of lasting success (Jacobs, B.L., Lee, C.T., Montie
2010). Clearly, there is a need for more effective bladder cancer screening in hopes of
diagnosing bladder cancers at earlier, more treatable stages. This has the potential to
significantly reduce bladder cancer mortality in the future.
1.2 Breast Cancer
Breast cancer is the second leading cause of cancer-related deaths among women
and constitutes 1 in 3 cancers diagnosed among United States women (Desantis et al.
2011). Due to the high prevalence of breast cancer, there is a need to develop better
prognostic as well as diagnostic markers of breast cancer that will aid in the treatment
and diagnosis of the disease. Risk factors for breast cancer include those that can be
modified as well as those that cannot be changed. Diet, lifestyle factors (i.e. exercise),
and estrogen exposure are factors that may be controlled or changed in response to risk
concerns. Among the risk factors that cannot be altered are age, race, genetic
susceptibility, sex, familial cancer diagnoses, and history of other benign breast lesions.
These risk factors also include the timing of the various stages of sexual development
including the age at which a women undergoes menarche, has a first successful
pregnancy (including the duration of breast-feeding), and the age at which a woman
undergoes menopause (Kamińska et al. 2015).
1.2.1 Diagnosis of Breast Cancer
Successful treatment of breast cancer depends on several factors, perhaps the most
important of which is early diagnosis. One contributing factor to early detection involves
routine breast cancer screening which typically consists of mammography as well as
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clinical and self-breast examination. While such screening has been effective in
identifying cases of breast cancer one major concern remains that generally by the time
that a patient has a palpable tumor, as identified by breast examinations, most cancers
have already progressed to a more advanced stage. Once screening identifies a patient of
concern for breast cancer more diagnostic testing is done. This can involve utilizing
additional imaging techniques (MRI or molecular breast imaging), sampling of breast
tissue (biopsy), and testing for known tumor markers (Anderson et al. 2015; Nounou et
al. 2015).
1.2.2 Prognostic Markers for Breast Cancer
Following initial diagnosis, it is imperative that each cancer is well-characterized
for type and grade. Breast cancer is divided into either ductal or lobular subtypes, each of
which may exhibit noninvasive or invasive phenotypes. Invasive ductal carcinoma
constitutes 55% of breast cancers at the time of diagnosis (Makki 2015). Additionally,
breast cancer is further subdivided using various molecular characteristics. The common
molecularly classified subtypes include: luminal A, luminal B, HER2 positive, and basallike. The most common of these subtypes is luminal A, which makes up about 50% of all
invasive breast tumors. Generally luminal A cancers express estrogen receptor (ERα) and
the progesterone receptor (PR) and do not express HER2. Making up around 20% of
invasive breast cancers are those of the luminal B subtype which do express ERα and PR
but which exhibit HER2 expression to various degrees. Cancers of this subtype tend to
have a range of responses to endocrine based treatments. About 15% of invasive breast
cancers are of the subtype characterized by the overexpression of HER2 and a lack of
expression of ERα or PR. For breast cancers highly expressing HER2, there is a greater
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probability of the cancer being higher in grade and having undergone metastasis to the
lymph nodes. Finally, 15% of invasive breast cancers may be categorized as basal-like in
exhibiting gene expression similar to basal epithelial cells. These have also become
known as triple-negative breast cancers as they do not express ERα, PR, or HER2 while
they do usually express the epidermal growth factor receptor (EGFR) and cytokeratins 5
and 6. Characterization of these molecular subtypes is essential as it indicates which
subtypes are likely to have a poorer prognosis and which will be either resistant or
responsive to the various available therapies. This in turn will aid in deciding on which
course(s) of treatment will be most advantageous for each breast cancer patient (Makki
2015).
1.2.3 Current Breast Cancer Treatments
Following diagnosis and characterization of breast cancer cases, a course of
treatment must be decided upon. Generally treatment options include surgery and/or a
combination of local or systemic treatments including chemotherapeutics, radiation, or
endocrine therapies (Nounou et al. 2015). The age of the patient may also play a role in
deciding treatment course as younger patients generally have unique concerns from those
of older patients. Among these concerns are decreased fertility, longer survivorship and
need for screening, and the potential impact that treatment may have on the patient’s
ability to work and care for their families. Complicating these issues is the fact that, as
younger women are not encouraged to undergo routine breast screening, it is more likely
that younger patients with breast cancers are diagnosed with cancers advanced to higher
stages (Partridge et al. 2012; Ademuyiwa et al. 2015). In metastatic breast cancers,
generally a two-tiered treatment plan may be considered. Initial treatment may consist of
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a combination of endocrine therapies whereas other strategies may be needed if these are
unsuccessful. (Reinert and Barrios 2015).
1.3 Arsenic and Cadmium as Environmental Carcinogens
This laboratory is interested in the identification of biomarkers that indicate
potential human exposure to environmental agents, particularly heavy metals. Arsenic, a
metalloid, and cadmium (Cd2+), a heavy metal, are known to be carcinogenic and
previous studies have suggested a link between arsenic and Cd2+ exposure and breast
cancer risk (Soh et al. 2011). In fact, arsenic and Cd2+ are two of the four metals known
to be carcinogenic in humans, the other two metals being chromium and nickel (Ernst and
Theriault 1984). Both arsenic and Cd2+ have been officially recognized as human
carcinogens according to the International Agency for Research on Cancer (IARC)
(Navarro Silvera and Rohan 2007).
1.3.1 Arsenic Metabolism
As an environmental carcinogen, arsenic is found naturally in the soil and water
of certain geographic areas. It can also be found as airborne particles when associated
with industrial areas (Arita and Costa 2009). Arsenic exposure also occurs through the
diet when eating seafood, mushrooms, poultry, and rice grown in contaminated areas
(Jomova et al. 2011). Humans are generally exposed to arsenic through contaminated
drinking water or occupational exposure in some industries (Navarro Silvera and Rohan
2007). Generally arsenic is found in either organic or inorganic arsenic (iAs) forms and it
is the inorganic form that has generally been shown to exhibit toxicity (Jomova et al.
2011). The body metabolizes iAs through oxidation-reduction reactions and methylation.
Methylation becomes important as it can actually increase toxicity. Arsenic is also known
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to bind to thiol groups or to glutathione which may also aid in detoxification when
binding to a protein, effectively preventing further toxic reactions (Carter, Aposhian, and
Gandolfi 2003; Luster and Simeonova 2004).
Most commonly, arsenic is ingested as a trivalent inorganic species. Arsenic can
be secreted in urine but some species have been known to accumulate in the body for as
long as several months before being cleared. Inorganic arsenic has two primary forms:
arsenite (As3+) or arsenate (As5+). Glutathione (GSH) is responsible for the conversion of
As5+ into As3+ after which methylation can occur to generate organic arsenic forms
(Jomova et al. 2011). During metabolism both forms can be either di- or tri-methylated.
Arsenite can be bound to three thiol groups by GSH or converted to monomethyl arsenic
(MMA) or dimethyl arsenic (DMA) by arsenic methyltransferases (Figure 1).

Figure 1 – The Metabolism of Inorganic Arsenic. Reproduced from Jomova et al. 2011
with permission from John Wiley and Sons.
7

1.3.2 Arsenic Toxicity and Carcinogenesis
With exposure to even low levels of arsenic, risk of several forms of cancer have
been shown. These include cancers of the skin, bladder, liver, kidney, and lung (Arita and
Costa 2009). Several sources have demonstrated that contaminated drinking water can
lead to cancer, including specifically bladder cancer (Smith et al. 1992; Steinmaus et al.
2000). Arsenic is capable of causing carcinogenic changes through several mechanisms, a
couple of which are known to include changes in cell differentiation and growth. In
addition, iAs exposure has been demonstrated to induce chromosomal abnormalities
(Navarro Silvera and Rohan 2007). Other potential mechanisms include interference with
DNA repair, alteration of DNA methylation patterns, direct cytotoxicity, the induction of
oxidative stress, and influence on signaling pathways (Pershagen 1981; Kitchin and
Wallace 2008; Arita and Costa 2009).
1.3.3 Arsenic and Bladder Cancer
In bladder cells, arsenic is able to increase cell proliferation through the
stimulation of the mitogen-activated protein kinase (MAPK) and extracellular-signal
related kinase (ERK) signaling pathways (Luster and Simeonova 2004). This may
contribute to the uncontrolled growth which is definitive of cancer. Furthermore, arsenic
exposure has been well-established as a link to bladder cancer occurrence through several
epidemiological studies. Looking at several of these studies, there is still some debate as
to the levels of iAs exposure that increase the probability of bladder cancer and even
whether low doses are linked to bladder cancer at all. Taken together however, it appears
that iAs exposures as low as100-150 μg/L may represent a baseline level for which a link
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to bladder cancer incidence occurs, especially when combined with smoking (Letašiová
et al. 2012; Cohen et al. 2013; Saint-Jacques et al. 2014).
1.3.4 Arsenic and Breast Cancer
The relationship between arsenic and breast cancer has yet to be fully elucidated
but from what is known, it is a complex interaction. One study has demonstrated that in
utero exposure to arsenic impacts mammary tissue development and increases the risk of
developing breast cancer later in life (Parodi et al. 2015). On the other hand, arsenic
trioxide has been used in some attempts to treat breast cancer, particularly as a means to
re-establish sensitivity to endocrine therapy (Zhang et al. 2011) or paclitaxel
(Bakhshaiesh et al. 2015) and to work with mammalian target of rapamycin (mTOR)
inhibitors to increase anti-tumor activity (Guilbert et al. 2013). Arsenic has been shown
to stimulate the epithelial to mesenchymal transition (EMT) in breast cells, with the
possible generation of a cancer stem cell population within transformed cells (Xu, Erik J.
Tokar, and Waalkes 2014).
Further complicating the relationship between arsenic and breast cancer is the fact
that arsenic is known to act as a metalloestrogen to disrupt normal endocrine signaling,
with serious repercussions for breast cancers. It appears that arsenic can have both ERαdependent and –independent mechanisms of action, either of which may induce or impact
breast cancers (Davey et al. 2007; Xu, Erik J. Tokar, and Waalkes 2014). One study in
MCF-10A cells has demonstrated that arsenic exposure can transform ERα-negative
breast epithelium into a cell line exhibiting the common features of triple-negative breast
cancers, which usually exhibit poor prognosis and are resistant to chemotherapeutic
treatment (Xu, Erik J. Tokar, and Waalkes 2014).
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1.3.5 Cadmium Metabolism
Exposure to Cd2+ generally results from cigarette smoking, occupational exposure
(including metal industries), or through the diet (Navarro Silvera and Rohan 2007; Arita
and Costa 2009). Of particular concern in the case of Cd2+ exposure is that the human
body is not equipped to metabolize Cd2+, therefore it accumulates in the body and it is not
easily secreted (Arita and Costa 2009; Martinez-Zamudio and Ha 2011). Cadmium can
be retained in the body for longer than 20 years before it is secreted. Generally
detoxification occurs via binding to proteins that contain thiol groups (such as GSH),
which leads to the production of oxidative stress and can eventually alter gene expression
patterns, arresting the cell cycle, inducing differentiation and immortalization, or
triggering apoptosis (Martelli et al. 2006). One of the more well understood proteins
known to aid in the detoxification of Cd2+ are those in the metallothionein superfamily.
Metallothioneins contain multiple cysteine amino acids which give them a very high
affinity for certain metals, including Cd2+. While binding to metallothionein, Cd2+ is
prevented from undergoing further reactions, resulting in detoxification (Klaassen, Liu,
and Choudhuri 1999; Klaassen, Liu, and Diwan 2009).
1.3.6 Cadmium Toxicity and Carcinogenesis
Cadmium is believed to stimulate carcinogenesis through various genotoxic
means: apoptosis inhibition, single-stranded DNA breaks, DNA repair inhibition,
mismatch repair inactivation, stimulation of oxidative stress, interference with cell-cell
connections, and proto-oncogene activation (Navarro Silvera and Rohan 2007; Arita and
Costa 2009; Feki-Tounsi and Hamza-Chaffai 2014). Of obvious interest when
considering carcinogenic mechanisms is that Cd2+ can inactivate the tumor suppressor
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protein p53, through a mechanism that appears to involve interference with the zincbinding sites which usually activate p53 (Hartwig 2013). Another study noted differences
in the p53 response to Cd2+ depending on the concentration; lower doses of Cd2+
appeared to activate p53 (possibly leading to apoptosis) through the generation of
reactive oxygen species (ROS) and stabilization of p53 structure. On the other hand,
higher doses of Cd2+ appeared to inhibit p53 activity by inducing conformational changes
which interfere with the ability of p53 bind to zinc preventing p53 activation (Méplan,
Mann, and Chem 1999). Cadmium exposure has also been linked to other diseases
including kidney and cardiovascular disease as well as effects on lung and mammary
tissue (Satarug et al. 2010).
1.3.7 Cadmium and Bladder Cancer
Epidemiological studies have indicated that there is a link between Cd2+ exposure
and bladder cancer risk (Feki-Tounsi and Hamza-Chaffai 2014). In Belgium, one study
demonstrated a connection between higher blood Cd2+ levels and increased risk of
bladder cancer. The odds ratio (OR) for Cd2+ exposure was 8.3 with a 95% confidence
interval (CI) once adjusted for age, gender, and occupational exposures to either aromatic
amines or polycyclic aromatic hydrocarbons. When also controlled for smoking, the OR
for Cd2+ remained significant at 5.7 (Kellen et al. 2007). One study evaluated the
interactions between arsenic and Cd2+ in relation to bladder cancers using exposed
Tunisian men. The results suggested that there was an increased blood Cd2+
concentrations in bladder cancer patients, especially smokers where blood Cd2+ levels
were nearly doubled compared to non-smokers once controlled for other confounding
factors. Overall, data showed that the OR for blood Cd2+ levels was 4.10 (95% CI)
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compared to participants also exhibiting increased blood As3+ levels which exhibited a
2.10 OR (Feki-Tounsi et al. 2013). At least one other study compared urine Cd2+ levels
between controls and patients with transitional cell carcinoma of the bladder. Results
indicated a correlation between increased Cd2+ concentrations and the presence of
transitional cell carcinoma. This study determined the effect of Cd2+ to have an OR of
7.11 for urinary Cd2+ when controlled for total protein (95% CI). It is also interesting to
note that nearly all of the Cd2+ found in the urine samples of this study were bound to
metallothionein (Wolf, Strenziok, and Kyriakopoulos 2009).
1.3.8 Cadmium and Breast Cancer
High urinary Cd2+ levels have been linked to an increased risk for breast cancers,
in part due to the ability of Cd2+ to function as a metalloestrogen. A meta-analysis of
case-control and cross sectional studies found a combined OR of 2.24 for Cd2+ levels in
breast cancer cases comparing participants with the highest Cd2+ levels to those with the
lowest (Larsson, Orsini, and Wolk 2015). As a metalloestrogen, Cd2+ is known to bind to
and activate ERα, resulting in the activation of several signal transduction pathways
which could contribute to the unregulated growth of mammary cells (Byrne et al. 2013).
This ERα activation would potentially have further repercussions in breast cancers,
affecting the ability of the tumor to respond to some treatments, especially those that are
endocrine or hormone based.
1.4 Anterior Gradient 2
1.4.1 AGR2 Function
Originally identified in Xenopus laevis, anterior gradient 2 was found to be
responsible for differentiation of the cement gland and shown to play a role in ectodermal
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patterning (Aberger et al. 1998). The human analog of the anterior gradient 2 (AGR2)
gene is of great interest due to the roles it performs in the endoplasmic reticulum stress
response and as a proto-oncogene in various human cancers. One primary known
function of AGR2 is that it is a member of the protein disulfide isomerase (PDI) family of
chaperone proteins (Persson et al. 2005; Park et al. 2009; Higa et al. 2011; Shishkin et al.
2013).
Primarily, AGR2 is known to function within the endoplasmic reticulum, though
there is evidence to suggest that it is secreted in gastrointestinal mucus (Park et al. 2009;
Bergström et al. 2014). Anterior gradient 2 is normally expressed in mucus-secreting
cells such as that of the lung, trachea, stomach, colon, prostate, and small intestine where
it is known to play a role in mucin production and secretion (Missiaglia et al. 2004).
Additional functions of AGR2 are still somewhat unclear, beyond its role as a PDI as part
of the cellular response regulating endoplasmic reticulum stress (Higa et al. 2011). One
role for AGR2 that is of great interest for this project is that of a proto-oncogene in
various cancers.
One very recent study has begun to clarify roles for extracellular or plasma
membrane localized AGR2. This study found that growth, migration, and cell cycle
progression were all increased in the MCF-7 cell line in response to the presence of
extracellular AGR2. They were also able to demonstrate that ERα can signal for AGR2 to
relocalize from the endoplasmic reticulum to the plasma membrane. The same study
showed that AGR2 interacts extracellularly with ERα and the insulin-like growth factor 1
(IGF-1) receptor and that these interactions influence cell growth, migratory ability,
progression through the cell cycle, and EMT (Li et al. 2016). Another recent study
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revealed that extracellular AGR2 can influence extracellular matrix function, leading to
changes in the tumor microenvironment. Here AGR2 was also shown to disrupt contacts
between cells by inducing the loss of E-cadherin (Fessart et al. 2016).
1.4.2 AGR2 as a Protein Disulfide Isomerase
Human AGR2 was identified as a member of the PDI family in 2005. As a
member of this family, the AGR2 gene is known to have some of the common
characteristics of PDIs, including a CXXC, or thioredoxin, motif which plays a role in
oxidation and reduction reactions, enabling AGR2 to interact with misfolded proteins by
forming disulfide bridges. Protein disulfide isomerases are able to oxidize, reduce, or
isomerize these disulfide bonds to correct improperly folded domains in client proteins
(Persson et al. 2005). Another common property of PDIs is a localization to the
endoplasmic reticulum. In AGR2 endoplasmic reticulum localization is accomplished by
the presence of a KTEL retention sequence, which is similar to the more well-understood
and frequently seen KDEL sequence (Fourtouna et al. 2009; Park et al. 2009).
1.4.3 AGR2 Protein Interactions and Effects
While performing it’s normal function as a PDI, AGR2 is known to interact with
mucin 2 (MUC2), preparing it for secretion and maintaining endoplasmic reticulum
homeostasis (Park et al. 2009; Bergström et al. 2014). Anterior gradient 2 is also known
to bind and act as a molecular chaperone for reptin (Maslon et al. 2010; Chevet et al.
2013). Reptin functions as a tumor repressor and is known to impact the progression of
cancer cells to metastasis (Kim et al. 2006). While most of the exact mechanisms have
yet to be studied, AGR2 has been demonstrated to impact the expression of several
proteins of particular interest due to their known roles implicated in tumorigenesis or
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cancer progression. Most of these cancer-associated roles seem to correspond to
extracellular or plasma membrane-associated AGR2. Perhaps the most obvious link to
cancer is the ability of AGR2 to silence p53 expression, interfering with the cells ability
to respond to DNA damage and initiate repair pathways (Pohler et al. 2004). One study
has suggested that Cyclin D1 may be activated downstream of AGR2 resulting in
increased cell growth and progression through the cell cycle (Vanderlaag et al. 2010).
Extracellular AGR2 has been shown to bind C4.4A and dystroglycan, suggesting
a possible role for AGR2 in metastasis (Fletcher et al. 2003). One study demonstrated
that AGR2 can activate YAP1 via dephosphorylation resulting in the activation of the
hippo pathway and the induction of AREG expression. In turn, AREG has been shown to
have a role in tumorigenesis and the regulation of cell growth (Dong et al. 2011). In
pancreatic cancer, AGR2 has been shown to be an indicator of poor prognosis and AGR2
upregulation can increase metastasis through the post-transcriptional regulation of
Cathepsin B and D expression (Ramachandran et al. 2008; Dumartin et al. 2011;
Brychtova et al. 2014). It has also been reported that AGR2 has the ability to enable
cancer cells to escape normal cell death mechanisms through signaling mechanisms
which increase survivin expression (Vanderlaag et al. 2010). Additionally, AGR2 appears
to interact with ERα, which has implications specifically in hormone-responsive cancers
(Vanderlaag et al. 2010).
1.4.4 AGR2 Gene Regulation
The regulation of AGR2 is not completely understood but there are a few
mechanisms known to regulate AGR2 expression. Most notably, the inositol requiring 1
(IRE1) and activating transcription factor 6 (ATF6) pathways of the unfolded protein
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response are known to induce AGR2 expression (Higa et al. 2011). In response to
extracellular stimuli, the ERK pathway has been shown to induce AGR2 expression
(Zweitzig et al. 2007). There have also been a few studies which suggested the possibility
that As3+ could induce AGR2 expression. These related studies have demonstrated that in
utero exposure of mice to iAs resulted in offspring exhibiting increased ERα expression
and increased expression of related genes, including AGR2 (Liu et al. 2007; Shen et al.
2007; Liu et al. 2008). In specific relation to cancers, AGR2 is known to be induced by
ERα and has been shown to be repressed by erb-b2 receptor tyrosine kinase 3 (ErbB3) in
prostate cancers (Vanderlaag et al. 2010; Zhang et al. 2010; Verma et al. 2012; Salmans,
Zhao, and Andersen 2013). One more recent study was able to demonstrate that IGF-1
can induce AGR2 expression using an estrogen-response element (ERE) and an activator
protein 1 (AP-1) site on the AGR2 promoter. This mechanism was shown to involve the
ERK, protein kinase B (AKT), and ERα signaling pathways. The IGF-1-mediated
induction of AGR2 occurred either with or without estrogen but was demonstrated to
require ERα (Li et al. 2015).
1.4.5 AGR2 in Cancers
The anterior gradient homolog 2 protein is known to be expressed in a wide
variety of cancers including carcinomas of the ovaries, colon, thyroid, pancreas, breast,
prostate and lung (Liu et al. 2005; Zhang et al. 2005; Bu et al. 2011; Darb-Esfahani et al.
2012; Pizzi et al. 2012; Kani et al. 2013; Di Maro et al. 2014; Riener et al. 2014). The
AGR2 protein is also known to be involved in various tumor associated pathways which
include those involved in tumor growth, cellular transformation and metastasis (Liu et al.
2005; Wang, Hao, and Anson W Lowe 2008). Further implications for an impact of
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AGR2 on the progression of cancer include the previously discussed interactions it has
with Cathepsins B and D, C4.4a, dystroglycan, yes-associated protein 1 (YAP1), and
amphiregulin (AREG) (Fletcher et al. 2003; Wang, Hao, and Anson W Lowe 2008; Dong
et al. 2011; Dumartin et al. 2011).
Regulation of the epithelial to mesenchymal transition (EMT) is another possible
role of AGR2 (Bu et al. 2011; Ma et al. 2015; Mizuuchi et al. 2015). This is of significant
interest as cells with the ability to undergo EMT are characteristic of metastatic cancers.
A connection between AGR2 and EMT seems to have been originally suggested in Bu et
al. 2011, a study which determined that AGR2 is upregulated in prostate cancers.
Concurrently it was observed that in AGR2 overexpression and knockdown studies, a
significant effect occurred in the ability of the cells to proliferate and metastasize. These
changes exhibited characteristics similar to what is seen in the actions of some
transcription factors known to have roles in stimulating EMT during both development
and in various cancers (Bu et al. 2011). Another study demonstrated that AGR2
expression can be regulated by known EMT inducers in a subset of prostate cancers
(Mizuuchi et al. 2015). An AGR2-involving EMT pathway was also demonstrated to
exist in glioblastoma cases (Xu et al. 2015).
1.4.6 AGR2 and Bladder Cancer
Studies have suggested that while the bladder normally expresses AGR2, it does
not usually secrete AGR2 in the urine or express AGR2 on the cell surface. This suggests
that AGR2 typically remains localized to the endoplasmic reticulum in normal bladder
epithelium. On the other hand, bladder cancers have been shown to exhibit lower cellular
AGR2 expression in general and bladder cancer patients tended to exhibit detectable
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secreted AGR2 in urine specimens. This suggests that overall AGR2 expression may be
relatively unchanged, rather it is the localization of AGR2 that is important for indicating
the presence of bladder cancer. It appears that rather than being retained in the
endoplasmic reticulum, AGR2 becomes secreted in the presence of bladder cancer. The
presence of secreted AGR2 in the blood or urine is therefore a potential biomarker for
bladder cancer among other cancers (Ho et al. 2016).
1.4.7 AGR2 in Breast Cancer
In breast cancer, AGR2 is known to be estrogen receptor responsive and is
overexpressed in estrogen receptor positive (ERα-positive) breast cancers (Thompson and
Weigel 1998; Fletcher et al. 2003; Pohler et al. 2004; Innes et al. 2006; Salmans, Zhao,
and Andersen 2013). While AGR2 expression has been demonstrated to have significant
prognostic meaning in ERα-positive breast cancers, less is known about the effect of
AGR2 in ERα-negative breast cancers. It is of interest to note that, though not well
understood, AGR2 has been shown to act through ERα-independent mechanisms
(Zweitzig et al. 2007). It has been shown that AGR2 may play a role in the metastasis of
breast cancer and is an indicator of poor prognosis (Fletcher et al. 2003; Fritzsche et al.
2006; Innes et al. 2006; Barraclough et al. 2009; Lacambra et al. 2015). Furthermore,
AGR2 is known to increase cell proliferation and survival in breast cancers through
interactions with cyclin D1, ERα, and survivin (Vanderlaag et al. 2010). Research has
also linked AGR2 expression to Tamoxifen resistance in breast cancers (Hrstka et al.
2010; Hengel et al. 2011; Wright et al. 2014).
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1.4.8 AGR2 and the Unfolded Protein Response
It is known that AGR2 plays a role in the cellular response to endoplasmic
reticulum stress. The pathway responsible for initiating AGR2 in response to stress is the
unfolded protein response. In the presence of cellular stress such as misfolded proteins,
cells can initiate signaling through the activating transcription factor (ATF6), double
stranded RNA-activated protein kinase (PRK)-like endoplasmic reticulum kinase
(PERK), and inositol requiring 1 (IRE1) transmembrane proteins. The downstream
signaling pathways of ATF6 and IRE1 are known to initiate AGR2 transcription and
translation. AGR2, in turn binds misfolded client proteins via disulfide bonds (Higa et al.
2011).
1.5 Experimental Models
1.5.1 UROtsa
UROtsa is a model of transitional cell carcinoma arising from SV40 large T
antigen-immortalized-human urothelial cells. The UROtsa cell line was initially cultured
from the urothelial lining of a 12-year old female. This new cell line was therefore
immortalized but did not display characteristics consistent with tumor cells as they did
not grow colonies when cultured on soft agar plates or form tumors upon injection into
nude mice (Petzoldt et al. 1995). This lab has further evaluated the UROtsa cell line and
determined that it is a good model for human urothelium and useful for the evaluation of
the stress response and responses to environmental toxicants, including As3+ or Cd2+. In
this study UROtsa cells were cultured in serum-free media and were demonstrated to
form cell layers with features consistent with in situ urothelium, particularly those of the
intermediate layers of transitional epithelium (Rossi et al. 2001). Additionally, the
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UROtsa cell line was transformed by exposure to 1 μM sodium arsenite (NaAsO2) or 1
μM cadmium chloride (CdCl2) so that six As3+ and seven Cd2+-transformed cell lines
were created. These cell lines were also injected into nude mice and allowed to form
tumors. Together, the cell lines and tumors have formed a model for arsenic and Cd2+induced bladder cancers, which allows for the study of and comparison between the in
vitro cultured transformed cell lines and their corresponding heterotransplant tumors, a
more in vivo approach (Sens et al. 2004). Upon microarray analysis comparing the
transformed cell lines to the non-transformed UROtsa, several differentially expressed
genes were identified and may be investigated as potential biomarkers for As3+ and Cd2+induced bladder cancers. (Garrett et al. 2014).
1.5.2 MCF-10A
The MCF-10A cell line is a human breast epithelial cell line, obtained from a 36year old Caucasian female with fibrocystic disease. MCF-10A is known to have
undergone spontaneous immortalization and is not tumorigenic when injected into nude
mice. Previously, the MCF-10A cell line was obtained by this laboratory and transformed
by exposure to 1 μM NaAsO2 or 1 μM CdCl2. These As3+ and Cd2+-transformed cell lines
were evaluated for an ability to grow in soft agar, indicating anchorage independent
growth. Further characterization has demonstrated that the MCF-10A parent cell line and
corresponding As3+ and Cd2+-transformed cell lines are a good model of metal-induced
breast cancers (Soh et al. 2011).
1.6 Intent and Goals of Study
This study was intended to answer several questions aimed at improving
understanding regarding the role(s) of AGR2 in cancers. The two main objectives were to
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demonstrate whether AGR2 has a role in bladder cancers and in breast cancers. This
study also sought to gain a better understanding about the function of AGR2 in these
cancers and to elucidate a possible mechanism by which AGR2 expression is regulated in
cancers. These objectives stem from the hypothesis that the proto-oncogene AGR2 is a
useful biomarker for breast and bladder cancers resulting from exposures to As3+ and
Cd2+. Anterior gradient 2 is expressed in the normal bladder urothelium and it has been
shown that the expression of AGR2 decreases within the cell while AGR2 secretion
increases as the grade and stage of urothelial cancers increases (Ho et al. 2016).
Immunohistochemical analysis was utilized to determine the expression of AGR2 in
human bladder cancer specimens and to evaluate whether the expression of AGR2 could
be used as a prognostic or diagnostic marker for bladder cancer. This laboratory has
developed an in-vitro model of bladder cancer by transforming the normal urothelial cell
line UROtsa with As3+ and Cd2+. A microarray analysis of the transformed cells showed
that transformation of the UROtsa cells with As3+ increased the expression of the protooncogene AGR2 and this study attempted to validate the microarray results using realtime PCR analysis and western blotting. The increased AGR2 expression seen in
transformed UROtsa cell lines could be attributable to the differences between in vitro
cell culture models and in vivo tissue or animal models. The expression of AGR2 in
tumor heterotransplants derived from the As3+ and Cd2+-transformed UROtsa cell lines
was determined in order to evaluate whether the effect of As3+ or Cd2+ would remain or
increase in an in vivo model. This led to the question of whether short term As3+ or Cd2+
exposure could induce AGR2 expression in UROtsa cells.
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Previously this laboratory has also shown that chronic exposure of the normal
breast epithelial cell line MCF-10A to As3+ or Cd2+ results in the transformation of these
cells (Soh et al. 2011). This prompted investigation into whether AGR2 expression was
differentially expressed in the MCF-10A model of metal induced breast cancers using
real-time PCR analysis and western blotting. Similar to the previous evaluation of AGR2
in the bladder, it was next determined whether short term exposure to As3+ or Cd2+ could
induce the expression of AGR2 in the parent MCF-10A cells. Previous studies have
suggested that overexpression of AGR2 can increase the growth and migratory potential
of breast cancer cells, therefore this study sought to determine whether the
overexpression of AGR2 in the MCF-10A cells would increase the growth and migratory
potential of these cells. For this purpose, the parent MCF-10A cells were transfected with
the AGR2 gene and the growth rate and migratory potential of the parent, As3+-and Cd2+transformed MCF-10 cells and the AGR2 transfected cells were determined using the
MTT and the wound scratch assays.
Other studies have shown that expression of AGR2 is associated with the estrogen
receptor alpha (ERα) status of the breast tumors, therefore was asked whether ERα
expression is present in the MCF-10A model using real-time PCR analysis. Since
methylation and histone modification are two of the mechanisms that are involved in the
regulation of gene expression, this study determined whether either of these mechanisms
could be responsible for the regulation of AGR2 in MCF-10A cells. To address this
question, MCF-10A cells were treated with the demethylating agent 5’-azacytidine (5AZC) or the histone deacetylase (HDAC) inhibitor, Entinostat (MS-275) after which realtime PCR analysis was used to determine AGR2 expression. It is known that cancer cells
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can secrete AGR2 and therefore this study attempted to determine whether AGR2 is
secreted by MCF-10A cells. Immunohistochemical localization of AGR2 in a variety of
different breast cancers was also determined to evaluate whether the expression of AGR2
correlated to particular grades or subtypes of breast cancers.
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CHAPTER 2
METHODS
2.1 Cell Culture
UROtsa cells were obtained from from the American Type Culture Collection
(ATCC) (Rockville, MD) and were grown in Dulbecco’s Modified Eagles Medium
(DMEM) (Sigma-Aldrich, St. Louis, MO; D5523) supplemented with 5% (v/v) FBS
(Gibco/Invitrogen, Grand Island, NY; 16000-044). Cells were supplied with fresh media
every 3 days or upon confluency. Subculture was also completed upon confluency using
0.25% Trypsin-EDTA (Gibco/Life Technologies, Carlsbad, CA; 25200-072) and
reseeding at a split ratio of 1:4. J82 (HTB-1), RT4 (HTB-2), and HT-1376 (CRL1472)
cell lines were obtained from ATCC and cultured in DMEM (Sigma-Aldrich, St. Louis,
MO; D5523) with 10% (v/v) FBS (Gibco/Invitrogen, Grand Island, NY; 16000-044), 5
mg/ml glucose (Fisher Scientific, Pittsburgh, PA; D16-500), and 1x nonessential amino
acids (Gibco/Invitrogen, Grand Island, NY; 11140). Cells were given fresh media every
2-3 days or upon confluency and were subcultured at a split ratio of 1:3 upon confluency
using 0.25% Trypsin-EDTA (Gibco/Life Technologies, Carlsbad, CA; 25200-072).
MCF-10A cells were obtained from ATCC and were grown in 1:1 DMEM
(Sigma-Aldrich, St. Louis, MO; D5523): Ham’s F12 Nutrient Mixture (Sigma-Aldrich,
St. Louis, MO; N6760). Culture media was supplemented with 5% (v/v) fetal bovine
serum (FBS) (Gibco/Invitrogen, Grand Island, NY; 16000-044), 20 ng/ml epidermal
growth

factor

(EGF)

(Gibco/Life
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Carlsbad,

CA;

PHG0311), 0.5 μg/ml hydrocortisone (Sigma-Aldrich, St. Louis, MO; HO135), 10 μg/ml
insulin (Sigma-Aldrich, St. Louis, MO; I2643), and 0.1 μg/ml cholera toxin (SigmaAldrich, St. Louis, CA; C8052). Cells were supplied with fresh media every 3 days or
upon confluency. Subculture was also completed upon confluency using 0.25% TrypsinEDTA (Gibco/Life Technologies, Carlsbad, CA; 25200-072) and reseeding at a split ratio
of 1:10. MDAMB-231, Hs578T, T47D, and MCF-7 cells were obtained from ATCC and
cultured using G-5 media consisting of DMEM (Sigma-Aldrich, St. Louis, MO; D5523)
with 5% (v/v) FBS (Gibco/Invitrogen, Grand Island, NY; 16000-044) and 5 mg/ml
glucose (Fisher Scientific, Pittsburgh, PA; D16-500). Cells were supplied with fresh
media every 2 days or upon confluency. Subculture was also competed upon confluency
using 0.25% Trypsin-EDTA (Gibco/Life Technologies, Carlsbad, CA; 25200-072) and
reseeding at a split ratio of 1:10.
2.2 Transformation of UROtsa Cells with As3+ and Cd2+
In order to evaluate the impact of As3+ and Cd2+ exposure on bladder cancers, a
model of metal-induced bladder cancers was made using the UROtsa bladder epithelial
cell line. In order to create this model, UROtsa cells were transformed by feeding cells
with media containing either 1 μM NaAsO2 (Sigma-Aldrich, St. Louis, MO) or 1 μM
CaCl2 (Sigma-Aldrich, St. Louis, MO). This exposure was continued and cells were
evaluated every 5 passages for the ability to form colonies in soft agar (Sens et al. 2004;
Cao et al. 2010; Somji et al. 2010). Once transformed with either metal, microarray
analysis was previously competed using the GeneChip human Genome U133 plus 2.0
arrays (Affymetrix, Santa Clara, CA) and was analyzed for global gene expression by
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Genome Explorations (Menphis, TN) in order to evaluate differential gene expression
patterns in response to either As3+ or Cd2+ (Talaat et al. 2011).
Previously, transformed UROtsa cell lines were used to generate heterotransplant
tumors. Using the transformed cell lines, 1 x106 cells were injected either subcutaneously
or intraperitoneally into nude mice. As formerly described, tumors were allowed to grow
for 10 weeks following subcutaneous injection or 53 days following intraperitoneal
injection, at which time mice were sacrificed and the tumors collected for analysis (Cao
et al. 2010; Somji et al. 2010). The UROtsa cell lines were also used to derive spheroids
as previously described (Slusser-Nore et al. 2016). Briefly, the transformed UROtsa cell
lines were cultured in ultra-low attachment flasks and supplied with serum-free medium
for 8 days. UROtsa spheroids were then harvested and processed for RNA and protein.
2.3 Exposure of UROtsa Cells to As3+ and Cd2+
In order to determine whether AGR2 is induced by either As3+ or Cd2+, time
course exposures were done using UROtsa cells. To determine the effect of As3+, UROtsa
cells were exposed to 2, 4, or 6 μM NaAsO2 (Sigma-Aldrich, St. Louis, MO) for 72
hours. For Cd2+, UROtsa cells were exposed to 1, 2, or 4 μM CdCl2 (Sigma-Aldrich, St.
Louis, MO) for up to 72 hours. For both As3+ and Cd2+ exposures, cells were harvested at
12, 24, 48, and 72 hours and processed to obtain RNA and protein.
2.4 Transformation of MCF-10A Cells with As3+ and Cd2+
In order to evaluate the impact of As3+ and Cd2+ on breast cancers, a model of
metal-induced breast cancers was made using the MCF-10A breast epithelial cell line. In
order to create this model, MCF-10A cells were transformed by feeding cells with media
containing either 1 μM NaAsO2 (Sigma-Aldrich, St. Louis, MO) or 1 μM CaCl2 (Sigma-
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Aldrich, St. Louis, MO). This exposure was continued and cells were evaluated every 5
passages for the ability to form colonies in soft agar (Soh et al. 2011). Once transformed
with either metal, microarray analysis was competed using GeneChip human Genome
U133 plus 2.0 arrays (Affymetrix, Santa Clara, CA) and was analyzed for global gene
expression by Genome Explorations (Memphis, TN) in order to evaluate differential gene
expression patterns in response to either As3+ or Cd2+.
2.5 Exposure of MCF-10A Cells to As3+ and Cd2+
In order to determine whether AGR2 is induced by either As3+ or Cd2+, time
course exposures were done using MCF-10A cells. To determine the effect of As3+,
MCF-10A cells were exposed to 1, 8, or 16 μM NaAsO2 (Sigma-Aldrich, St. Louis, MO).
For Cd2+, MCF-10A cells were exposed to 2, 4, or 8 μM CdCl2 (Sigma-Aldrich, St.
Louis, MO) for up to 48 hours. For both As3+ and Cd2+ exposures, cells were harvested at
12, 24, 36, and 48 hours and processed to obtain RNA and protein.
2.6 AGR2 Transfection of MCF-10A Cells
A construct containing AGR2 was made using the 6.2 V5-DEST vector and
obtained from Invitrogen (Carlsbad, CA). Amplification of the construct was
accomplished by transforming the plasmid into E. coli cells (OneShot-OmniMax 2-T1R;
Invitrogen/Life Technologies, Carlsbad, CA; C8540-03). Successfully transformed
colonies were selected using LB (Fisher, Pittsburgh, PA; BP1427-500) agar (Fisher,
Pittsburgh, PA; BP1423-500) plates with 100 μg/ml ampicillin. Transformed bacterial
colonies were inoculated into liquid LB and bacterial stocks were amplified and pelleted.
Plasmid preparation was done using the Endo-Free Maxi Prep Kit (Qiagen, Germantown,
MD; 12362). Prior to transfection, the AGR2 construct was linearized using BspHI (New
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England BioLabs, Ipswich, MA; R0517S) and purified using the GeneClean Kit (MPBio,
Santa Ana, CA; 111102-400). Stable transfection of 2 μg blank vector or 2 μg AGR2
vector was accomplished via electroporation using the Amaxa Cell Line Nucleofector Kit
L (Lonza, Allendale, NJ; VCA-1005). Colonies were selected using 20 μg/μl blasticidin S
HCl (BSD) (Gibco/Life Technologies, Carlsbad, CA; A11139-03).
2.7 Cell Viability and Doubling Times
In order to determine the effects of AGR2 expression on MCF-10A cell growth,
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction and
wound healing assays were used. The MCF-10A model was used for these assays,
including As3+ and Cd2+-transformed cell lines as well as MCF-10A cells transfected with
either blank 6.2 V5-DEST vector or a 6.2 V5 vector containing the coding regions of the
AGR2 gene. For proliferation, MTT assays were performed. Cells were seeded in 6-well
plates and allowed to grow for up to 6 days. Plates of cells were taken daily and exposed
to 100 mg/ml MTT (Sigma-Aldrich, St. Louis, MO; M5655) for 3.5 hours. Cells were
then rinsed twice with phosphate buffered saline and then with 1 ml acidic propanol.
Optical density was evaluated at 570 nm and data were used to calculate doubling times
for each cell line.
2.8 Wound/Scratch Assays
Cells were grown to confluency in 6-well plates and a scratch was made created
using a 100 μl pipette tip. The wells were washed twice with phosphate buffered saline
and fresh media was added to the cells. Images were taken right after the addition of
media (0 hours) and after 4, 8, and 12 hours in order to evaluate the levels of cell
migration into the wound. Percent wound closures were determined.
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2.9 RNA Isolation and Real-time RT-PCR
Cells were harvested using a cell scraper and pelleted via centrifugation. Total
RNA isolation was performed using TRI REAGENT (Molecular Research Center, Inc.
Cincinnati, OH; TR 118) according to supplied protocol and as previously outlined by
this laboratory (Somji et al., 2006). RNA was converted to cDNA using the iScript cDNA
Synthesis Kit (Bio-Rad Laboratories, Hercules, CA; 170-8890). Real-time PCRs were
run using iTaq Universal SYBR Green Superrmix (Bio-Rad Laboratories, Hercules, CA;
172-5124) or IQ SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA;
1708882). For Anterior Gradient 2 (AGR2) and Estrogen Receptor 1 (ESR1 or ERα),
QuantiTect Primer Assays (Qiagen) were obtained for the determination of mRNA
expression. These primer assays were Hs_AGR2_1_SG and Hs_ESR1_1_SG
respectively. Identical cycling parameters were used for AGR2 and ESR1 primers.
Cycling was done with denaturation at 95 ̊C for 15 sec, annealing at 62 ̊C for 45 sec, and
extension at 72 C
̊ for 30 sec. To aid in validation of construct expression, primers were
designed for the V5 tag of the 6.2 V5 DEST vector and obtained from Invitrogen (Grand
Island,

NY).

Primer

sequences

for

the

V5

tag

were

sense,

TTCGAAGGTAAGCCTATCCCT, and antisense, AGTCATTACTAACCGGTACGC.
Cycling parameters for V5 primers were denaturation at 95 ̊C for 15 sec, annealing at
55 ̊C for 45 sec, and extension at 72 ̊C for 30 sec.
2.10 Protein Extraction and Quantitation
Whole cell lysates were prepared using 1x SDS (Life Technologies, Carlsbad,
CA; 15525-017) Lysis Buffer and briefly sonicated to obtain cellular protein samples.
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Quantification of protein levels in each sample was done using the BCA assay kit
obtained from Thermo-Fisher Scientific (Waltham, MA; 23228 and 1859678).
2.11 Collection and Preparation of Spent Media
MCF-10A cells were cultured for 24 hours in serum free media in a T75 flask
prior to confluency. Spent media was collected and the cell monolayer was harvested
using a cell scraper. Spent media was prepared using Amicon® Ultra-15 centrifugal filters
with Ultracell® 3 membranes (EMD Millipore, Billerica, MA;UFC900308). Media was
centrifuged for 1 hour at 4 ̊C and 3700 relative centrifugal force (RCF) to concentrate
media samples. Total protein concentrations were then determined using the BCA assay
reagents (Thermo-Fisher Scientific, Waltham, MA; 23228 and 1859678).
2.12 Western Blot Analysis
Protein expression levels were determined using 10 or 20 μg of total cellular protein on 420% Mini-PROTEAN TGX Stain-Free Gels (Bio-Rad Laboratories, Hercules, CA; 4568094). AGR2 protein levels were detected using a rabbit monoclonal antibody to AGR2
(Abcam, Cambridge, MA; ab76473) at a 1:5,000 dilution and secondarily anti-rabbit IgG,
HRP-Linked antibody (Cell Signaling, Boston, MA; 7074S) at a 1:2,400 dilution. Beta
Actin protein levels were detected using a mouse monoclonal antibody to Beta-Actin
(Abcam, Cambridge, MA; ab8226) at a 1:1,000 dilution and secondarily anti-mouse IgG,
HRP-Linked antibody (Cell Signaling, Boston, MA; 7076S) at a 1:2,400 dilution.
Biotinylated markers were detected using anti-biotin-linked antibody (Cell Signaling,
Boston, MA; 7075S) at a 1:1,200 dilution. Antibody visualization was accomplished
using Clarity Western ECL Blotting Substrate (Bio-Rad Laboratories, Hercules, CA; 1705061).
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Table 1 – Western Antibody Sources
Antibody Target Company
AGR2
Abcam
Biotin secondary
Cell Signaling
Mouse secondary
Cell Signaling
Rabbit secondary
Cell Signaling
β-Actin
Abcam

Catalog Number
ab76473
7075S
7076S
7074S
ab8226

2.13 Immunofluorescent Staining of MCF-10A Cell Lines
MCF-10A cells were cultured on 12 mm glass coverslips in 24-well plates until
confluent. Cells were then rinsed twice with DMEM:F12 media containing no phenol red
and fixed in 3.7% paraformaldehyde (Polysciences, Warrington, PA; 18814-10) for 20
min. 0.1 M NH4Cl (Sigma, St. Louis, MO; A-5666) was used for 15 min to quench free
aldehyde groups and cells were permeabilized for 30 min using 0.3% Triton-X100
(Fisher Scientific, Pittsburg, PA; BP151-100). Cells were incubated for 1 hour in AGR2
primary antibody (Abcam, Cambridge, MA; ab76473) at a 1:600 dilution. Alexa
Fluor®488 goat anti-rabbit IgG secondary antibody (Life Technologies, Carlsbad, CA;
A11008) was used for 1 hour at a 1:1,000 dilution. Stained coverslips were then mounted
in ProLong® Diamond Antifade Mountant with DAPI (Life Technologies, Carlsbad, CA;
P36971). Anterior gradient 2 immunofluorescence was visualized using a Leica DM5500
Q TCS SPE confocal microscope. Z-slice images were captured and processed using
LAS-X software.
2.14 Immunohistochemical Analysis of Tumors and Tumor Specimens
UROtsa heterotransplant tumors were formalin-fixed and embedded in paraffin
prior to immunohistochemical analysis. Formalin-fixed paraffin-embedded breast and
bladder cancer specimens were also used for immunohistochemical analysis. Specimens
from archival paraffin blocks were 10 years post diagnosis and scheduled for disposal as
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medical waste. These archival specimens contained no patient identifiers and are in the
exempt category for human research. Sections of transplanted tumors were cut into 3-5
µm thick slices for use in immunohistochemical protocols. The primary antibody used
was AGR2 (Abcam, Cambridge, MA; ab76473) at a 1:500 dilution for 30 minutes.
Immunohistochemical staining was performed on Leica Bond-Max Automated IHC
Staining System (Leica, Bannockburn, IL). Paraffin sections were processed starting with
deparaffinization and ending with counterstaining by hematoxylin according to the
manufacturer’s recommended program with modification. Bond Polymer Refine
Detection (Leica, DS9800) was used as the main reagent in the automatic staining
process. Briefly, the major steps include deparaffinization, antigen retrieval in Bond
Epitope Retrieval Solution 1 (Leica, Catalog No AR9961) for 20 min, peroxide block for
5 min, incubation with primary antibodies for 30 min at room temperature, incubation
with Post Primary for 10 min, incubation with polymer for 10 min, visualization with
3,3’-diaminobenzidine (DAB) for 10 min, and counterstaining with hematoxylin for 5
min. Slides were rinsed in distilled water, dehydrated in graded ethanol, cleared in
xylene, and coverslipped. The presence and degree of immunoreactivity in the specimens
was judged by two pathologists. The scale used was 0 to +3 with 0 indicating no
staining, +1 staining of mild intensity, +2 staining of moderate intensity, and +3 staining
of strong intensity. All immunohistochemical preparation, staining, and analysis were
performed by Dr. Xudong Zhou.
2.15 Treatment of MCF-10A Cells with 5-Azacytidine and MS-275
MCF-10A cells were fed with media containing 1, 3, or 10 μM Entinostat (MS275) (ALEXIS Biochemicals, Lausen, Switzerland) or 1, or 3 μM 5’-azacytidine (5-AZC)
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(Sigma-Aldrich, St. Louis, MO) for 72 hours. Following exposure, cells were harvested
to obtain cell pellets which were processed to obtain RNA and protein as described
above.
2.16 Statistical Analysis
Statistical analysis was conducted using GraphPad Prism® 5.0 software. Real-time
PCR and western I.O.D. analysis was analyzed in triplicate and evaluated using an
unpaired T-test when comparing two samples. When comparing multiple samples either
one-way analysis of variance (ANOVA) with a post-hoc Tukey multiple comparison test
or two-way ANOVA with Bonferroni post-hoc tests were used for statistical analysis.
Asterisks are used to denote statistically significant differences compared to the control
sample as follows: * (p < 0.05), ** (p < 0.01) and *** (p < 0.001).
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CHAPTER 3
RESULTS
3.1 Expression of AGR2 in Bladder Cancers
Analysis of AGR2 expression in urothelial cancers by Ho and coworkers (2016)
showed strong staining of AGR2 in normal urothelium, but in urothelial cancer AGR2
expression was lost, with only 25% of primary tumors observed to retain expression in a
cohort

of

lymph

node

positive

cases.

The

present

study

examined

the

immunohistochemical localization and expression of AGR2 in a small sample set: five
specimens of benign urothelium; four cases of low grade urothelial cancer; five cases of
high grade, non-invasive urothelial cancer; and, five cases of high grade, muscle invasive
urothelial cancer. Immunohistochemical staining, imaging, and analysis were done by
Xudong Zhou. All five specimens of normal urothelium showed moderate cytoplasmic
staining of AGR2 throughout the urothelium, with lesser staining in the umbrella cells
(black arrow) forming the outer layer of the bladder epithelium (Figure 2 A). This is not
surprising as bladder epithelia have been shown to express AGR2 (Ho et al. 2016). The
underlying smooth muscle cells showed no staining for AGR2. As illustrated for one
specimen with moderate/heavy staining for AGR2, all four cases of low grade urothelial
cancer stained positive for AGR2. The staining of the four specimens varied between
moderate and strong and over 80% of the urothelial cancer cells in all specimens were
positive for the expression of AGR2 (Figure 2 B). The expression of AGR2 in nonmuscle invasive urothelium was variable with four cases showing moderate staining in 70
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to 80% of the urothelial cells (one specimen illustrated as Figure 2 C) and two cases with
moderate staining but with only 5% of the urothelial cells staining positive for AGR2
(one specimen illustrated as Figure 2 D). The expression of AGR2 was also variable in
high grade, muscle invasive urothelial cancer. Three specimens of high grade, muscle
invasive bladder carcinoma were negative for the expression of AGR2 (two specimens
illustrated in Figure 2 E and F with 2 F having an internal control with staining for benign
urothelium). The other two specimens showed weak to moderate staining for AGR2 in
30% of the cells (Figure 2 G) and the other moderate to strong staining in over 80% of
the cells (Figure 2 H). These data demonstrate variability in AGR2 expression among
high-grade and invasive urinary carcinomas. A summary of AGR2 staining in bladder
cancers specimens is provided in Table 2. In this table, the intensity of AGR2 staining in
benign epithelium (if present) was scored. Also evaluated were the intensity of AGR2
staining in tumor cells and the overall percentage of tumor cells stained for AGR2 for
each slide evaluated. Overall, these results indicate that AGR2 expression can be lost in
the presence of bladder cancers.
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Figure 2 – AGR2 Staining in Urothelial Carcinomas. A: Normal bladder urothelium.
B: Low grade non-invasive urothelial carcinoma of the ureter. C: High grade noninvasive urothelial carcinoma of the bladder. D: High grade non-invasive urothelial
carcinoma with focal areas suspicious for invasion. E-H: High grade invasive urothelial
carcinomas of the bladder.
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Table 2 – Summary of AGR2 Staining in Specimens of Urothelial Carcinoma.
Tumor type, AGR2 staining intensity, and percentage of cells positive for AGR2 staining
for each tumor evaluated. LG – low grade, HG – high grade, LG ca. w/f HG – low grade
carcinoma with focal high grade, NA – not applicable (no benign or tumor cells present),
- denotes no staining observed
AGR2
Lesion
Benign
Intensity Percentage
Epithelium
Benign Urothelium
3+
NA
NA
Benign Urothelium
2+
NA
NA
LG carcinoma
3+
2-3+
80
LG carcinoma
NA
3+
80
LG ca. w/f HG
NA
2-3+
80
HG Noninvasive
NA
2-3+
5
HG Noninvasive
NA
2-3+
70
HG Noninvasive
NA
3+
80
HG Noninvasive
NA
3+
80
HG Invasive
3+
HG Invasive
NA
2-3+
30
HG Invasive
3+
HG Invasive
3+
HG Invasive
NA
HG Invasive
NA
3+
80
LG Benign Tissues
NA
3+
80
3.2 Expression of AGR2 in UROtsa Cells Transformed with As3+ or Cd2+
As this laboratory is primarily interested in evaluating the effect that As3+ and
Cd2+ have on various cancers, a model for As3+ and Cd2+-induced urothelial cancers has
previously been established using the UROtsa bladder epithelial cell line. Briefly, the
UROtsa cell line was exposed to 1 μM NaAsO2 or 1 μM CdCl2, resulting in the formation
of six As3+ and seven Cd2+-transformed UROtsa cell lines. These UROtsa cell lines have
been shown to be a good model for heavy metal induced urothelial carcinomas (Rossi et
al. 2001). Gene expression changes in the transformed UROtsa cell lines were evaluated
using microarray analysis and compared to that of the non-transformed UROtsa cell line.
One of the genes determined to be upregulated in response to transformation with As3+
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was AGR2, which was induced 4.87 fold over parent (Garrett et al. 2014). Anterior
gradient 2 expression in the bladder is of interest as it has been identified as a biomarker
for advanced bladder cancers when secreted in the blood or urine (Ho et al. 2016). The
next goal for this study was to evaluate AGR2 expression in the UROtsa model of heavy
metal induced bladder cancers. Real-time PCR and western analysis were used to
determine AGR2 expression in As3+ and Cd2+-transformed UROtsa cell lines. The data
showed that AGR2 is significantly upregulated in four of the As3+ and six of the Cd2+transformed UROtsa cell lines (Figure 3 A and D). Western analysis also confirmed an
increase in AGR2 protein in the majority of the As3+ and Cd2+-transformed cell lines
(Figure 3 B-C and E-F). Complicating the analysis is that the western blotting for AGR2
exhibited evidence of post-translational modification, seen as two separate bands and/or
as smeared bands. This requires using a generous area when integrating optical density
for further analysis rather than a tight area around a single band, affecting the integrated
optical density (I.O.D.) analysis of western blotting for AGR2 (Figure 3 B-C and E-F).
This has been observed in other publications studying AGR2 and may indicate the Oglycosylation of secreted AGR2. At least one previous study demonstrated that the Oglycosylation of AGR2 may affect extracellular functions (Clarke, Rudland, and
Barraclough 2015). This secondary or smeared band therefore makes it challenging to
visualize the full impact of the changes to AGR2 protein expression which may account
for some of the variability between mRNA and protein expression. Results indicate that
AGR2 expression increases following transformation of UROtsa cells with As3+ or Cd2+.
Transformed UROtsa cell lines were injected into nude mice and allowed to form
heterotransplant tumors. These heterotransplant tumors were evaluated for AGR2
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expression using real-time PCR. Only two of the As3+ heterotransplant tumors retained
significantly increased AGR2 expression (Figure 4 A). Four of the Cd2+ heterotransplant
tumors

maintained

significantly

increased

AGR2

expression

(Figure

4

B).

Immunohistochemical staining of As3+ and Cd2+ heterotransplant tumors was done to
further evaluate AGR2 expression. Results showed that heterotransplant tumors arising
from arsenic-transformed UROtsa cell lines #1, #3, and #6 exhibited AGR2 staining
though all tumors had a small population of cells with moderate staining (Figure 5). In
tumors derived from the Cd2+-transformed UROtsa cell lines, AGR2 staining was
strongest in cell lines #2, #5, and #6. Once again, all tumors exhibited a population with
moderate AGR2 staining (Figure 6). A summary of the immunohistochemical staining is
provided in Table 3. These results show that AGR2 expression is induced in urothelial
cancers arising from As3+ and Cd2+-transformed cells. In turn, this suggests that As3+ and
Cd2+ are capable of inducing tumorigenesis in urothelial cells.
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Figure 3 – AGR2 Expression in As3+ and Cd2+-transformed UROtsa Cell Lines. A:
Real-time PCR analysis of AGR2 expression in UROtsa cells transformed with As3+. B:
Western analysis of AGR2 in As3+-transformed UROtsa cell lines. C: I.O.D. analysis of
western data in B, plotted as AGR2/β-Actin. D: Real-time PCR analysis of AGR2
expression in UROtsa cells transformed Cd2+. E: Western analysis of AGR2 in Cd2+transformed UROtsa cell lines. F: I.O.D. analysis of western data in E, plotted as
AGR2/β-Actin. *** denotes (p < 0.001) and ** (p < 0.01) statistically significant
difference from parent UROtsa cells. Real-time and western I.O.D. data is plotted as the
mean ± SEM of triplicate determinations.
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Figure 4 – AGR2 Expression in Heterotransplant Tumors from As3+ and Cd2+transformed UROtsa Cell Lines. A: Real-time PCR analysis of AGR2 expression in
heterotransplant tumors arising from As3+-transformed UROtsa cell lines injected into
nude mice. B: Real-time PCR analysis of AGR2 expression in heterotransplant tumors
arising from Cd2+-transformed UROtsa cell lines injected into nude mice. Real-time data
is plotted as the mean ± SEM of triplicate determinations.
41

Figure 5 – AGR2 Staining in UROtsa As3+ Heterotransplants. A: UROtsa As #1
tumor. B: UROtsa As #2 tumor. C. UROtsa As #3 tumor. D: UROtsa As #4 tumor. E:
UROtsa As #5 tumor. F: UROtsa As #6 tumor. G: Low grade bladder carcinoma.
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Figure 6 – AGR2 Staining in UROtsa Cd2+ Heterotransplants. A: UROtsa Cd #1
tumor. B: UROtsa Cd #2 tumor. C: UROtsa Cd #3 tumor. D: UROtsa Cd #4 tumor. E:
UROtsa Cd #5 tumor. F: UROtsa Cd #6 tumor G: UROtsa Cd #7 tumor.
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Table 3 – Summary of AGR2 Staining in UROtsa Heterotransplant Tumors.
Intensity of AGR2 staining and percentage of cells positive for AGR2 staining.
AGR2
Group
Intensity Percentage
UROtsa As #1
2+
10
UROtsa As #2
1-2+
<5
UROtsa As #3
2-3+
50
UROtsa As #4
1+
<5
UROtsa As #5
2+
5
UROtsa As #6
2+
20
UROtsa Cd #1
1-2+
<5
UROtsa Cd #2
3+
70
UROtsa Cd #3
2-3+
20
UROtsa Cd #4
2-3+
30
UROtsa Cd #5
2-3+
60
UROtsa Cd #6
3+
70
UROtsa Cd #7
2+
10
LG urothelial carcinoma
3+
80
3.3 Expression of AGR2 in UROtsa Cells Exposed to As3+ or Cd2+
Next, this study sought to evaluate whether AGR2 expression can be induced by a
short-term exposure to either As3+ or Cd2+. UROtsa cells were exposed to 2, 4, or 6 μM
NaAsO2 or 1, 2, or 4 μM CdCl2 for up to 72 hours. Expression of AGR2 increased within
48 hours in response to As3+ exposure (Figure 7 A). For the most part, significant
induction of AGR2 in response to Cd2+ exposure was not seen. Notable increases in
AGR2 expression did occur by 48 hours with 2 μM Cd2+ and at 72 hours with 1 μM Cd2+.
Significant decrease in AGR2 expression occurred at 48 hours with exposure to 4 μM
Cd2+. These decreases are likely attributable to the toxicity exhibited by the UROtsa cells
at this concentration of Cd2+ (Figure 7 B). Results suggest that there is little to no
significant effect of As3+ or Cd2+ exposure on the induction of AGR2 in UROtsa cells.
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Figure 7 – AGR2 Expression in UROtsa Cells Exposed to As3+ or Cd2+. A: Real-time
PCR analysis of AGR2 expression in UROtsa cells exposed to 2, 4, or 6 μM As3+ for up
to 72 hours. B: Real-time PCR analysis of AGR2 expression in UROtsa cells exposed to
1, 2, or 4 μM Cd2+ for up to 72 hours. *** denotes (p < 0.001), ** (p < 0.01), and * (p <
0.05) statistically significant difference from untreated UROtsa cells harvested with each
time point. Real-time data is plotted as the mean ± SEM of triplicate determinations.
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3.4 Expression of AGR2 mRNA in Cancer-Initiating-Cells (CICs) Isolated from the
As3+ and Cd2+-transformed UROtsa Cell Lines
This laboratory has extended the UROtsa model of As3+ and Cd2+-induced bladder
cancers to include spheroids isolated from the transformed cell lines by culturing the cell
lines in serum-free media and in low attachment flasks. Previous studies by this group
shown that these spheroids express high levels of aldehyde dehydrogenase 1 (ALDH1)
and form subcutaneous tumor transplants identical to those of the As3+ and Cd2+transformed cells (Sandquist et al. 2016; Slusser-Nore et al. 2016). This fulfills the
requirement that these spheroids represent cancer-initiating cells (CICs). The expression
of AGR2 mRNA was determined on total RNA isolated from the spheroids isolated from
the As3+ and Cd2+-transformed cell lines and all the spheroids were shown to express
AGR2 mRNA (Figure 8 A and B). Tumors generated from the CICs in the above two
studies (Sandquist et al. 2016; Slusser-Nore et al. 2016) for two of the As3+-transformed
cell lines and two of the Cd2+-transformed cell lines were examined for their expression
of AGR2 protein using immunohistochemistry. The staining for AGR2 was similar to
that found above for tumors generated directly from the cultured cell lines; cytoplasmic,
focal, and associated with the more undifferentiated cells of the tumor (Figure 9). The
results showed that between 20 to 30% of the tumor cells of all four tumor transplants
stained moderately to strongly (+2 to +3) for the expression of AGR2 protein (Table 4).
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Figure 8 – AGR2 Expression in CICs Derived from As3+ and Cd2+-transformed
UROtsa Cell Lines. A: Real-time PCR analysis of AGR2 expression in spheroids
derived from the As3+-transformed UROtsa cell lines. B: Real-time PCR analysis of
AGR2 expression in spheroids derived from the Cd2+-transformed UROtsa cell lines. ***
denotes a (p < 0.001), ** (p < 0.01), and * (p < 0.05) statistically significant difference
from spheroids derived from the non-transformed parental UROtsa cell line. Real-time
data is plotted as the mean ± SEM of triplicate determinations.
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Figure 9 – AGR2 Staining in UROtsa-derived CICs. A: UROtsa As #1 spheroid
derived tumor. B: UROtsa As #3 spheroid derived tumor. C: UROtsa As #6 spheroid
derived tumor. D: UROtsa Cd #1 spheroid derived tumor. E: UROtsa Cd #4 spheroid
derived tumor.
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Table 4 – Summary of AGR2 Staining in Heterotransplant Tumors from UROtsaderived CICs. Tumor type, AGR2 staining intensity, and percentage of cells positive for
AGR2 staining for each tumor evaluated. LG – low grade.
AGR2
Group
Tumor Type Intensity Percentage
UROtsa As #1
Spheroid
3+
20
UROtsa As #3
Spheroid
2-3+
30
UROtsa As #6
Spheroid
2-3+
20
UROtsa Cd #1
Spheroid
2-3+
30
UROtsa Cd #4
Spheroid
3+
30
LG urothelial carcinoma
NA
3+
80
3.5 AGR2 Expression in Urothelial Carcinoma Cell Lines
After evaluating AGR2 expression in As3+ and Cd2+-transformed UROtsa cell
lines and corresponding heterotransplant tumors, this study next sought to evaluate AGR2
expression in three commercially-available urothelial carcinoma cell lines. Real-time
PCR and western analysis were used to determine AGR2 expression in the J82 (HTB-1),
RT4 (HTB-2), and HT-1376 (CRL1472) cell lines, which had been previously obtained
from ATCC. The J82 cell line was obtained from a 58-year old Caucasian male with
transitional cell carcinoma. The RT4 cell line was isolated from a transitional cell
papilloma in a 63-year old Caucasian male. The HT-1376 cell line was isolated from a
58-year old Caucasian female with grade 3 urothelial carcinoma. Results showed that
AGR2 mRNA is expressed in all three urothelial carcinoma cell lines but is most highly
expressed in the RT4 and HT-1376 cell lines (Figure 10 A). Western analysis also
showed that AGR2 is expressed in all three of the urothelial carcinoma cell lines and that
it has the greatest expression in the RT4 cell line (Figure 10 B and C). These results
demonstrate that AGR2 expression is present in bladder cancer cell lines.
Next, this study determined whether AGR2 expression remains elevated in tumors
derived from the urothelial carcinoma cell lines. Tumors were generated for the urothelial
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carcinoma cell lines by injecting each cell line subcutaneously or intraperitoneally into
nude mice. Slides made from the isolated tumors were stained for AGR2 expression
using immunohistochemical techniques. Results indicate positive AGR2 staining in
subcutaneous and intraperitoneal tumors arising from the HT-1376 cell line (Figure 11 A
and B). Tumors derived from subcutaneous or intraperitoneal injection of the J82 cell line
did not exhibit staining for AGR2 (Figure 11 C and D). Strongly positive AGR2 staining
was seen in subcutaneous tumors derived from the RT4 cell line (Figure 11 D and F). An
intraperitoneal tumor derived from the RT4 cell line exhibited strong AGR2 staining in
tumor cells (Figure 11 G). A further summary of these results is shown in Table 5. These
results indicate that only the HT-1376 and RT4 derived tumors were able to maintain
elevated AGR2 expression, which is consistent with these cell lines exhibiting the highest
AGR2 expression.
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Figure 10 – AGR2 Expression in Urothelial Carcinoma Cell Lines. A: Real-time PCR
analysis of AGR2 expression in urothelial carcinoma cell lines. Real-time data is plotted
as the mean ± SEM of triplicate determinations. B: Western blot analysis of AGR2 in
urothelial carcinoma cell lines. C: I.O.D. analysis of western blotting in B, plotted as
AGR2/β-Actin.
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Figure 11 – AGR2 in Heterotransplants from Urothelial Carcinoma Cell Lines. A:
Subcutaneous HT-1376 tumor. B: Intraperitoneal HT-1376 tumor. C: Subcutaneous J82
tumor. D: Intraperitoneal J82 tumor. E: Subcutaneous RT4 tumor. F: Subcutaneous RT4
tumor. G: Intraperitoneal RT4 tumor.
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Table 5 – Summary of AGR2 Staining in Heterotransplants from Urothelial
Carcinoma Cell Lines. Tumor type, AGR2 staining intensity, and percentage of cells
positive for AGR2 staining for each tumor evaluated.
AGR2
Cell Line Tumor Type Intensity Percentage
HT-1376 Subcutaneous
3+
30
HT-1376 Intraperitoneal
3+
40
J82
Subcutaneous
0
J82
Intraperitoneal
0
RT4
Subcutaneous
3+
100
RT4
Intraperitoneal
3+
100
3.6 Expression of AGR2 in MCF-10A Cells Transformed with As3+ or Cd2+
In order to better understand the impact of As3+ and Cd2+ on breast cancers, a
model for heavy metal-induced breast cancer has previously been established using the
MCF-10A breast epithelial cell line (Soh et al. 2011). Previous microarray analysis and
subsequent studies on how As3+ and Cd2+ affect the expression of AGR2 in the UROtsa
model of heavy metal-induced bladder cancers prompted the question of whether similar
effects might be seen in the MCF-10A model. In order to see if AGR2 may also serve as
a biomarker for heavy metal-induced breast cancers, the expression of AGR2 was
determined in the MCF-10A parent and the As3+ and Cd2+-transformed cells using realtime PCR and western analysis. Real-time PCR analysis showed a significant increase in
AGR2 expression in the As3+-transformed MCF-10A cell line compared to nontransformed MCF-10A cells. A significant decrease in AGR2 expression was seen in the
Cd2+-transformed MCF-10A cell line (Figure 12 A). Western blotting of whole cell
lysates was used to evaluate AGR2 protein expression in the transformed MCF-10A cell
lines. The results also indicated a significant increase in AGR2 protein expression
following As3+-transformation and a significant decrease in AGR2 protein following
Cd2+-transformation compared to non-transformed MCF-10A cells (Figure 12 B and C).
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These results indicate that AGR2 expression is increased in response to transformation
with As3+ but not Cd2+ in MCF-10A cells.

Figure 12 - Expression of AGR2 mRNA and Protein in As3+ and Cd2+-transformed
MCF-10A Cells. A: Real-time PCR analysis of AGR2 mRNA in As3+ and Cd2+transformed MCF-10A cells. ***Denotes a statistically significant difference from MCF10A parent cells (p < 0.001). Real-time data is plotted as the mean ± SEM of triplicate
determinations. B: Western blot analysis of AGR2 and protein in As3+ and Cd2+transformed MCF-10A cells. F: I.O.D. analysis of western blotting in C, plotted as
AGR2/β-Actin.
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3.7 Expression of AGR2 in MCF-10A Cells Exposed to As3+ or Cd2+
After having established that As3+-transformation can result in increased AGR2
expression, this study next sought to determine whether AGR2 expression is induced by
exposure to As3+ or Cd2+. In order to evaluate the effect that As3+ exposure has on AGR2
expression, MCF-10A cells were exposed to 4, 8, or 16 μM NaAsO2 for up to 48 hrs.
Cells were harvested 12, 24, 36, and 48 hours following treatment and analyzed by realtime PCR and western analysis to determine AGR2 expression. Data indicate that AGR2
expression was significantly increased in response to As3+ exposure. By 36 hours, 2, 3.6,
and 4.9 fold increases in AGR2 mRNA was seen at 4, 8, and 16 μM As3+ exposure
respectively (Figure 13 A). Furthermore, western blotting followed by I.O.D. analysis
indicated as much as a 7.5 fold increase in AGR2 protein expression after 36 hours
exposure to 16 μM As3+ (Figure 13 B and C). Additionally, this study sought to establish
whether Cd2+ is capable of inducing AGR2 expression. To accomplish this, MCF-10A
cells were exposed to 2, 4, or 6 μM CdCl2 for 12, 24, 36, or 48 hours and were analyzed
using real-time PCR for AGR2 expression. The data obtained indicated that there was a
transient increase in the expression of AGR2 at 12 hour of exposure with 4 μM Cd2+,
however the levels went down by 24 hours (Figure 14). These results demonstrate that
As3+ is capable of inducing AGR2 expression in MCF-10A cells while AGR2 expression
is not induced by Cd2+ exposure.
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Figure 13 - Expression of AGR2 mRNA and Protein in As3+-exposed MCF-10A
Cells. MCF-10A cells were exposed to 4, 8, or 16 μM As3+ for 12, 24, 36, or 48 hrs and
the expression level of AGR2 was determined. A: Real-time PCR analysis. Asterisks
denote a statistically significant difference from 0 μM As3+ within each time point with *
(p < 0.05), ** (p < 0.01) and *** (p < 0.001). Real-time data is plotted as the mean ±
SEM of triplicate determinations. B: Western blot analysis of AGR2 expression in MCF10A cells exposed to As3+. C: I.O.D. analysis of western data in B, plotted as AGR2/βActin.
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Figure 14 - Expression of AGR2 mRNA in Cd2+-exposed MCF-10A Cells. Real-time
PCR analysis of AGR2 transcripts in MCF-10A cells exposed to 2, 4, or 6 μM Cd2+ for
12, 24, 36, or 48 hrs. Asterisks denote a statistically significant difference from 0 μM
Cd2+ within each time point with * (p < 0.05), ** (p < 0.01) and *** (p < 0.001). Realtime data is plotted as the mean ± SEM of triplicate determinations.
3.8 AGR2 Expression in Breast Cancer Cell Lines
Previous studies have demonstrated that AGR2 expression is correlated to breast
cancers, specifically subtypes which commonly exhibit poor prognosis (Fritzsche et al.
2006; Barraclough et al. 2009; Lacambra et al. 2015) . Since the expression of AGR2 is
correlated to the ERα status (Thompson and Weigel 1998; Innes et al. 2006; Salmans,
Zhao, and Andersen 2013), this study sought to determine AGR2 expression in
commercially available breast cancer cell lines that are widely used as in-vitro models of
breast cancer. For this purpose, breast cancer cell lines known to have different ERα
expression profiles were utilized. Real-time PCR and western analysis were used to
determine AGR2 expression in two ERα-negative (MDAMB-231 and Hs578T) and two
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ERα-positive (T47D and MCF-7) breast cancer cell lines. Results showed the greatest
increase of AGR2 mRNA expression in the T47D breast cancer cell line, moderate
increases in the MCF-7 and MDAMB cell lines, and essentially undetectable AGR2
expression in Hs578T cells (Figure 15 A). Western blotting analysis showed a similar
trend for AGR2 protein expression, with the greatest expression in the T47D cell line.
The MDAMB-231 and MCF-7 cell lines also exhibited increased AGR2 protein while
AGR2 was not detectable in the Hs578T cell line using western blotting (Figure 15 B and
C). These results suggest that AGR2 is highly expressed in a well-known ERα-positive
breast cancer cell line and exhibits lower expression in ERα-negative breast cancer cell
lines.
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Figure 15 - Expression of AGR2 mRNA and Protein in Breast Cancer Cell Lines. A:
Real-time PCR analysis of AGR2 expression in breast cancer cell lines. Real-time data is
plotted as the mean ± SEM of triplicate determinations. B: Western blot analysis of
AGR2 in breast cancer cell lines. C: Integrated optical density (I.O.D.) analysis of
western blotting in B, plotted as AGR2/β-Actin.
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3.9 Role of ERα in MCF-10A Cells
Anterior gradient 2 expression has been shown to be influenced by estrogen
receptor (ERα) status in breast cancers (Thompson and Weigel 1998; Innes et al. 2006;
Salmans, Zhao, and Andersen 2013). This study next sought to further investigate
whether ERα has a role impacting AGR2 expression in the MCF-10A breast cell model.
Normally MCF-10A cells are known to be ERα-negative, however the possibility for
MCF-10A cells to begin expressing ERα has been demonstrated (Lane et al. 1999). With
this in mind real-time PCR analysis was used to evaluate ERα (ESR1) expression in 2
ERα-negative (MDAMB-231 and Hs578T) and 2 ERα-positive (T47D and MCF-7)
breast cancer cell lines as well as in parent and As3+ and Cd2+-transformed MCF-10A cell
lines. While ERα expression was confirmed in both ERα-positive breast cancer cell lines,
high ERα-expression was not seen in any of the MCF-10A cell lines (Figure 16). These
data suggest that the expression of AGR2 in MCF-10A cells is most likely due to ERαindependent mechanisms. This is especially true when evaluating the As3+ and Cd2+transformed MCF-10A cell lines. The non-transformed MCF-10A cell line did exhibit a
low level of ERα expression, therefore the possibility of ERα influences on AGR2
expression and function cannot be dismissed entirely in non-transformed MCF-10A cells.
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Figure 16 – ERα Expression in Breast Cancer and MCF-10A Cell Lines. Real-time
PCR analysis of AGR2 transcripts in breast cancer cell lines (MDAMB, Hs578T, T47D,
and MCF-7) as well as MCF-10A cell lines transformed with As3+ or Cd2+. Real-time data
is plotted as the mean ± SEM of triplicate determinations.
3.10 Effect of the Overexpression of AGR2 on MCF-10A Cell Proliferation
The next goal of this study was to investigate the functional impact that AGR2
expression has in breast tissue, especially as those functions may have significant impact
on the outcome of AGR2-expressing breast cancers. An AGR2-overexpressing MCF-10A
cell line was created which could be used to further elucidate the functions of AGR2 in
breast epithelia. Real-time PCR and western analysis were used to confirm AGR2
overexpression (Figure 17). These data indicate that an AGR2-overexpressing MCF-10A
cell line was generated and that this cell line will be useful for evaluating the functional
role of AGR2 in breast epithelia.
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As AGR2 expression has been known to affect cell proliferation and has been
previously associated with metastasis (Liu et al. 2005; Ramachandran et al. 2008; Wang,
Hao, and Anson W. Lowe 2008), the next goal of this project was to evaluate the growth
and migration potential of MCF-10A cells transformed with As3+ or transfected with
AGR2. In order to determine the effect of As3+ or Cd2+-transformation on MCF-10A cell
growth rates, MTT assays were utilized. The results obtained indicated a significant
increase in proliferation for As3+-transformed MCF-10A cells compared to the nontransformed MCF-10A cell line (Figure 18). Wound/scratch assays were performed on
MCF-10A cell lines in order to determine the migration potential of the cells. Images
were collected and analyzed from just after scratching (0 hr) and from 4, 8, and 12 hours
later. Wound closure rates were then determined in order to evaluate migration into the
wound. MCF-10A cells transformed with As3+ exhibited a 70.62% wound closure rate,
significantly increased over parent MCF-10A cells (48.03%) or Cd2+-transformed MCF10A cells (57.37%) (Figure 19). These results demonstrate that As3+-transformed cells
had an increased growth rate and migration potential when compared to the parent MCF10A cells and the Cd2+-transformed cells, suggesting a more tumorigenic phenotype in
As3+-transformed MCF-10A cells. While it may seem tempting to correlate the changes
in growth and migratory potential to the increased AGR2 expression exhibited by the
As2+-transformed MCF-10A cell line, there are any number of potential mechanisms to
which these effects may be attributed. Further studies will be needed to determine which
mechanism(s) may be involved.
We also wanted to determine if overexpression of AGR2 in MCF-10A cells
would have an effect on their growth rate and migration potential. In order to determine

62

the growth rate, MTT assays were performed on the MCF-10A cells transfected with
either the blank 6.2 V5-DEST vector or with an AGR2-containing construct. The data
obtained shows that overexpression of AGR2 in MCF-10A cells can increase their
growth rate when compared to cells transfected with the blank vector alone (Figure 20).
This project also sought to determine whether overexpression of AGR2 would affect the
migration potential of the MCF-10A cells transfected with AGR2 in a wound scratch
assay. Results show that overexpression of AGR2 in MCF-10A cells results in an
increase in the wound closure rate when compared to the blank vector (Figure 21). In
conclusion, these data suggest that overexpression of AGR2 can affect the growth rate
and migration potential of cells, hence its expression may have an effect on the metastatic
potential of breast cancer cells. To further verify the effect of AGR2 on the proliferation
and migration of MCF-10A cells, further experiments would need to be completed. These
experiments might include the knock-down of AGR2 expression in the As3+-transformed
and AGR2-transfected MCF-10A cell lines.
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Figure 17 - Expression of AGR2 mRNA and Protein in MCF-10A Cells Transfected
with AGR2. A: Real-time PCR analysis of AGR2 mRNA. B: Western analysis of AGR2
protein. C: I.O.D. analysis of Western data in B, plotted as AGR2/β-Actin.
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Figure 18 – Effect of As3+ and Cd2+-transformation on the Growth Rate of MCF-10A
Cells. The growth rates were determined by measuring the capacity of the cells to reduce
MTT to formazan. The cells were allowed to grow for 6 days and the ability of the cells
to reduce MTT was determined every day. All experiments were done in triplicates and
shown is the mean ± SEM absorbance values.
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Figure 19 – Effect of As3+ and Cd2+-transformation on the Migration of MCF-10A
Cells. MCF-10A parent and transformed cell lines were subjected to wound scratch assay
and migration of the cells was determined after 4, 8 and 12 hours. Percent wound
closures were calculated and are presented beneath the 12 hour panels for each cell line.
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Figure 20 - Effect of AGR2 Expression on the Growth Rate of MCF-10A Cells
Transfected with the Blank Vector or the AGR2 Gene. The growth rates were
determined by measuring the capacity of the cells to reduce MTT to formazan. The cells
were allowed to grow for 6 days and the ability of the cells to reduce MTT was
determined every day. All experiments were done in triplicates and shown is the mean ±
SEM absorbance values.
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Figure 21 - Effect of AGR2 Expression on MCF-10A Cell Migration. MCF-10A cells
were transfected with AGR2 or a blank vector and were scratched at confluency. The
ability of the cells to grow and migrate into the wound was determined after 4, 8 and 12
hours of incubation. Percent wound closures were calculated and are presented beneath
the 12 hour panels for each cell line.
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3.11 Localization of AGR2 in MCF-10A Cells
Normally AGR2 is seen localized to the endoplasmic reticulum and may be
secreted outside of the cell (Park et al. 2009; Bergström et al. 2014). In the case of AGR2
expression, it is of great interest to determine localization as it has been demonstrated that
AGR2 localization impacts its function (Gupta, Dong, and Lowe 2012; Chevet et al.
2013; Tsuji et al. 2014; Fessart et al. 2016; Li et al. 2016). There remains a need to better
understand how the cellular or extracellular localization of AGR2 impacts its function as
very few studies have addressed this question so far. This study next sought to determine
the localization of AGR2 in MCF-10A cells using immunofluorescence microscopy and
representative images are shown in Figure 22. Parent MCF-10A cells showed weak to no
AGR2 staining (Figure 22 A). While the AGR2-transfected MCF-10A cell line had cells
exhibiting the strongest AGR2 staining, there were smaller clusters of cells with this
strong staining rather than exhibiting staining throughout the population of cells. The
intense staining had a very apparent web-like appearance which was slightly more
localized to near the nucleus, indicative of endoplasmic reticulum localization (Figure 22
B). Staining in the As3+ and Cd2+-transformed MCF-10A cell lines showed populations of
cells with moderate to strong AGR2 staining also consistent with localization to the
endoplasmic reticulum (Figure 22 C and D). Overall, these results indicated that AGR2 is
mainly localized to the endoplasmic reticulum in each of the MCF-10A cell lines
evaluated. No apparent localization of AGR2 to secretory vesicles was seen which would
have exhibited a more widespread and punctate staining throughout the cytoplasm. This
suggests that AGR2 is mainly localized in the endoplasmic reticulum in MCF-10A cells
and likely mainly functioning as a PDI and in endoplasmic reticulum homeostasis.
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Figure 22 – AGR2 Localization in MCF-10A Cell Lines. Images of AGR2
immunofluorescence in MCF-10A cell lines. A: Parent MCF-10A B: AGR2-transfected
MCF-10A C: As3+-transformed MCF-10A D: Cd2+-transformed MCF-10A. Blue – DAPI
(nuclear) staining, Green – AGR2
3.12 Secretion of AGR2 in MCF-10A Cell Lines
Secretion of AGR2 has been shown to result in the initiation and progression of
various cancers, including that of the prostate (Ramachandran et al. 2008) and to promote
tumorigenic characteristics in MCF-7 cells (Li et al. 2015; Li et al. 2016). Recently it was
demonstrated that AGR2 secretion may serve as a useful biomarker for bladder cancers
(Ho et al. 2016). After having determined the cellular localization of AGR2 in MCF-10A
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cell line, the next aim was to verify whether AGR2 is secreted in MCF-10A cells. While
AGR2 did not appear to be localized to secretory vesicles, this possibility could not be
completely discounted. In order to further establish whether AGR2 is secreted,
conditioned media and cell monolayers were collected from As3+-transformed and
AGR2-transfected MCF-10A cells. Western analysis was performed in order to
determine whether AGR2 was secreted and conditioned media from T47D cells was used
as a positive control for secreted AGR2. Data indicated that AGR2 is not secreted in any
of the MCF-10A cell lines (Figure 23). This suggests that secretion does not have a
significant impact on AGR2 function in the MCF-10A cell line.

Figure 23 – AGR2 Secretion in MCF-10A cells. Western analysis of AGR2 expression
in cell lysate and conditioned media from T47D and MCF-10A cells transfected with
AGR2 or transformed by As3+.
3.13 Expression of AGR2 in Breast Cancers
The next goal was to determine the impact of AGR2 in breast cancers and to
evaluate whether AGR2 expression correlates with tumor type or grade. A panel of breast
cancers archived in paraffin blocks was used for immunohistochemical staining and
consisted of ductal carcinoma in situ (DCIS) and grade 1, 2, and 3 infiltrating ductal
carcinoma (IDC). Ductal carcinoma in situ is a subtype of breast cancers in which tumors
have arisen inside mammary ducts and has not exhibited invasion out of the duct.
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Infiltrating ductal carcinoma, also known as invasive ductal carcinoma, occurs when
breast cancers which originated in the mammary duct have progressed through the milk
duct and has potential to spread throughout mammary tissues or to metastasize to lymph
nodes. Tumors that are determined histologically to be well differentiated are classified
as Grade 1. Similarly grade 2 tumors are moderately differentiated and grade 3 represents
poorly differentiated tumors (AJCC 2010).
Specimens were stained for AGR2 expression using immunohistochemical
techniques in order to determine whether AGR2 expression correlates to stage or
progression of breast cancers. Normal breast tissues exhibited AGR2 staining in lobular
and ductal epithelial cells, with no observed staining in the surrounding myoepithelial
cells (Figure 24 A and B). Low grade DCIS exhibited moderate AGR2 staining while
high grade DCIS showed strong staining for AGR2 (Figure 24 C and D). Grade 1 IDCs
exhibited moderate to strong AGR2 staining (Figure 24 E and F). Grade 2 IDC exhibited
AGR2 staining in tumor cells, either in scattered tumor cells or localized in cancer nests
(black arrow) while benign ducts exhibited no AGR2 staining (Figure 25 A and B). One
section with both grade 2 IDC and intermediate grade DCIS exhibited strong AGR2
staining in the affected duct (DCIS – white arrow) and in the IDC nests (black arrow) to
either side the affected duct. No AGR2 staining was observed in the surrounding
myoepithelial cells (Figure 25 C). In benign breast cells from the same slide as Figure 25
C, results showed luminal epithelial cells (black arrow) positive for AGR2 staining while
outer myoepithelial cells did not show AGR2 staining (Figure 25 D). Another grade 2
IDC also exhibited strong AGR2 staining in cancer cells (Figure 25 E). One slide of
grade 3 IDC exhibited cancer nests (black arrow) strongly positive for AGR2 and which
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were moderately positive for AGR2 (Figure 25 F). Another grade 3 IDC exhibited
strongly AGR2 stained cancer nests (black arrow) with no AGR2 staining in two benign
ducts (white arrows) (Figure 25 G). Diffuse and strong positive AGR2 staining was also
seen in another grade 3 IDC (Figure 25 H). In summary, AGR2 staining of at least
moderate degree was seen in all tumor samples, as demonstrated in DCIS and Grade 1
IDC (Figure 24). The intensity of staining increased with increasing grades of breast
tumors, as seen in grade 2 and 3 IDCs (Figure 25). In most instances, the myoepithelial
cells surrounding the tumor did not exhibit significant AGR2 staining. Overall, this data
shows that increased AGR2 expression is correlated with higher grades of IDC,
suggesting that AGR2 is a biomarker for breast cancers.
The previously mentioned slides were also stained for ERα expression in an
attempt to discern whether hormone receptor status may correlate with AGR2 expression
and tumor subtype. Table 6 summarizes the results as determined by two pathologists.
Nine of the seventeen lesions evaluated demonstrated strong AGR2 and strong ERα
staining, with all but one of the grade 3 IDCs exhibiting strong staining for both. Of the
seven grade 2 IDCs, four exhibited strong staining for both AGR2 and ERα and two
showed moderate staining for both. There was one instance of no to weak staining for
both AGR2 and ERα. One of the grade 1 IDC lesions exhibited strong staining for AGR2
and ERα while the other lesion was weakly stained for AGR2 but strongly stained for
ERα. Neither the high grade or low grade DCIS lesion evaluated exhibited moderate or
strong ERα staining while the high grade DCIS showed strong AGR2 positivity. Benign
breast tissue exhibited moderate AGR2 and ERα staining (Table 6). This data suggests
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that there may be a correlation between AGR2 expression and the ERα status of the
tumor.

Figure 24 – AGR2 Staining in Benign, DCIS, and Grade 1 Infiltrating Ductal
Carcinoma of the Human Breast. A: Human benign breast tissue. B: Normal human
breast from breast reduction. C: Low grade DCIS. D: High grade DCIS. E-F: Grade 1
IDC.
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Figure 25 – AGR2 Staining in Grade 2 and 3 Infiltrating Ductal Carcinoma of the
Human Breast. A-B: Grade 2 IDCs. C: Grade 2 IDC and intermediate grade DCIS. D:
Benign breast tissue. E: Grade 2 IDC. F-H: Grade 3 IDCs.
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Table 6 – Immunostaining of AGR2 and ERα in Human Breast Carcinomas.
Summarizes AGR2 and ERα staining data from DCIS and IDC lesions as seen in Figure
24 and Figure 25. G1 – Grade 1, G2 – Grade 2, G3 – Grade 3, HG – High Grade, LG –
Low Grade
AGR2
ERα
Lesion
Intensity %
Intensity
%
IDC-G3
3+
90
3+
90
IDC-G3
3+
90
3+
90
IDC-G3
3+
90
2+
80
IDC-G3
3+
90
2-3+
60
IDC-G3
3+
80
2-3+
80
IDC-G3
2-3+
50
3+
90
IDC-G2
3+
90
3+
90
IDC-G2
3+
90
3+
90
IDC-G2
3+
90
3+
80
IDC-G2
2-3+
80
3+
90
IDC-G2
2-3+
70
2-3+
70
IDC-G2
3+
60
2+
60
IDC-G2
2+
<5
2+
20
IDC-G1
3+
90
3+
90
IDC-G1
2+
20
2-3+
80
DCIS-HG
3+
80
DCIS-LG
1-2+
10
2+
30
Benign
2-3+
50
3+
50
3.14 Epigenetic Regulation of AGR2 in MCF-10A and Breast Cells
At least one study has demonstrated that AGR2 expression can be regulated by
DNA methylation, increasing AGR2 expression and producing more aggressive ovarian
cancer phenotypes (Hirst and Marra 2009; Sung et al. 2014). This suggests a possible
mechanism for the induction of AGR2 expression in breast cancers. It was therefore
decided that it would be beneficial to further investigate epigenetic modifications as a
possible mechanism by which As3+ could induce AGR2 expression. DNA methylation is
considered to be associated with the decreased expression of gene transcription therefore
genes regulated by DNA methylation should exhibit increased expression in the presence
of DNA methylation inhibitors such as 5’-azacytidine (5-AZC) (Cedar 1988; Hirst and
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Marra 2009). Histone deacetylases (HDACs) are responsible for removing acetyl groups
from histones, resulting in the repression of gene expression (Struhl 1998). Inhibitors of
HDACs, such as Entinostat (MS-275), can be used in an attempt to restore gene
expression when regulation occurs via histone acetylation. MCF-10A cells were exposed
to 1, 3, or 10 μM MS-275 or either 1 or 3 μM 5-AZC for 72 hours. Data showed
increasing AGR2 expression with increasing doses of both HDAC and DMT inhibitors
(Figure 26). This suggests that both histone acetylation and DNA methylation play roles
in the regulation of AGR2 transcription in MCF-10A cells.
We next sought to determine whether histone acetylation or DNA methylation are
also active in regulating AGR2 expression in commercially available breast cancer cell
lines. In order to determine whether AGR2 expression is under epigenetic control,
MDAMB-231 and Hs578T cells were exposed to 1, 3, or 10 μM MS-275, or either 1 or 3
μM 5’-azacytidine (5-AZC) for 72 hours. Real-time PCR analysis was used to determine
AGR2 mRNA expression. Data indicated that AGR2 expression was not as highly
induced in MDAMB-231 cells as in MCF-10A cells, suggesting that AGR2 expression is
still partially regulated by both histone acetylation and DNA methylation in MDAMB231 cells (Figure 27 A). Hs578T, cells may be partially regulated by histone acetylation
but did not appear to be regulated by DNA methylation (Figure 27 B). Overall, these data
suggest that histone acetylation and DNA methylation may have roles in the regulation of
AGR2 transcription in various breast cancers. Further study is necessary in order to verify
the specific roles that histone acetylation and DNA methylation may play in AGR2
regulation. Both 5-AZC and MS-275 are known to affect global epigenetic regulatory
mechanisms as opposed to acting on specific acetylation or methylation sites. Until
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further studies are performed, it is possible that the effect of histone acetylation and DNA
methylation on AGR2 seen in the data presented in this study represent indirect effects.

Figure 26 – MCF-10A Expression of AGR2 in Response to MS-275 or 5-AZC. Realtime PCR analysis of AGR2 transcripts in MCF-10A cells exposed to MS-275 (1, 3, or 10
μM) or 5-AZC (1 or 3 μM) for 72 hours. Asterisks denote a statistically significant
difference from untreated MCF-10A cells with * (p < 0.05), ** (p < 0.01) and *** (p <
0.001). Real-time data is plotted as the mean ± SEM of triplicate determinations.
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Figure 27 – Expression of AGR2 in Response to MS-275 or 5-AZC in Breast Cancer
Cell Lines. Real-time PCR analysis of AGR2 transcripts in A: MDAMB and B: Hs578T
cells exposed to MS-275 (1, 3, or 10 μM) or 5-AZC (1 or 3 μM) for 72 hours. Asterisks
denote a statistically significant difference from untreated control (Ctl) cells with * (p <
0.05), ** (p < 0.01) and *** (p < 0.001). Real-time data are plotted as the mean ± SEM
of triplicate determinations.
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CHAPTER 4
DISCUSSION
4.1 AGR2 in the Bladder
This laboratory has examined the expression of AGR2 in a small set of archival
specimens of low grade and high grade urothelial cancers and found benign urothelium
and low grade tumors to have the most pronounced expression of AGR2, with high grade
non-invasive and high grade invasive cancers having absent or lower expression. This
finding is in agreement with the only previous study to examine AGR2 expression in
urothelial cancer (Ho et al. 2016). The expression of AGR2 in breast cancer correlates
with lower tumor grade, epidermal growth factor receptor negativity, and estrogen
receptor alpha (ERα) positivity (Fletcher et al. 2003; Innes et al. 2006). In breast cancer,
high AGR2 expression is associated with poor outcome in ERα-positive cancers and
hormonally treated breast cancers (Fritzsche et al. 2006; Barraclough et al. 2009; Hrstka
et al. 2010; Lacambra et al. 2015). An analysis of AGR2 mRNA expression in prostate
cancer also showed AGR2 to be upregulated in all tumors in general compared to benign
tissues, but with low grade tumors and prostatic intraepithelial neoplasia (PIN) lesions
having the highest expression of AGR2 compared to control (Bu et al. 2011). In addition,
transcripts of AGR2 were higher in Gleason score (GSC) 6 tumors when compared to
GSC 8-10 tumors, suggesting expression is decreased as grade increases. An analysis of
AGR2 expression in three commonly utilized human bladder cancer cell lines showed the
greatest expression of AGR2 in the culture isolated from a low grade urothelial cancer.
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While in general AGR2 expression appears to be lost or decreased in higher grade
tumors, the previous studies in breast, prostate and urothelial cancer also suggested a
poor prognosis when AGR2 expression does remain elevated in high grade cancers. In
prostate cancer, AGR2 expression has been shown to be elevated in circulating tumor
cells in the plasma from patients with metastatic prostate cancer (Kani et al. 2013).
Anterior gradient 2 expression in circulating cells was most pronounced in tumors with
neuroendocrine or anaplastic features with an aggressive clinical phenotype without
elevated circulating prostate specific antigen (PSA) levels. As noted above for breast
cancers, high AGR2 expression correlates to a poor prognosis in ERα-positive breast
cancers, and as detailed in the introduction, findings in urothelial cancer showed tumor
invasion fronts of primary tumors and lymph nodes from many of these primary tumors
to express AGR2. The findings in urothelial cancer suggest the hypothesis that AGR2
expression may favor the local spread of the tumor.
In an attempt to gain insight into AGR2 expression in urothelial cancer, AGR2
expression was explored employing As3+ and Cd2+-transformed UROtsa cells since the
expression of AGR2 could be examined during cell transformation in vitro and in in vivo
tumor transplants derived from these cells. Overall, the expression of AGR2 in the
independent isolates of the As3+ and Cd2+-transformed cells and derived tumors was
highly variable. The expression of AGR2 mRNA and protein was variable within the
independent isolates of the As3+ and Cd2+-transformed cell lines, with five of six of the
Cd2+ and four of seven of the As3+-transformed cell lines having mRNA levels
significantly elevated over control. The corresponding expression of the AGR2 protein
only weakly followed the AGR2 mRNA levels, with only modest elevations of protein in
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four of the six As3+ and in six of the seven Cd2+-transformed cell lines. The expression of
AGR2 mRNA and protein was also highly variable in the tumor transplants and AGR2
expression showed little or no relationship to the amount of AGR2 expressed in the
initiating cell line. The % of AGR2 staining cells in the tumor transplants from the
independently generated As3+ and Cd2+-transformed UROtsa cell lines varied from 5 to
70%. This demonstrates the ability of As3+ and Cd2+ to stimulate AGR2 expression in
urothelial cells.
This complements studies that have demonstrated the ability of AGR2 to have a
role in stimulating tumor cell proliferation and metastasis as well as studies that have
demonstrated the ability of AGR2 to impact the formation of xenograft tumors. One
study demonstrated the potential for AGR2 to induce metastasis and tumor formation
when transfection of a construct containing a cDNA sequence identical to that of AGR2
into Rama 37 rat mammary cells promoted a metastatic phenotype when injected in
syngeneic rats (Liu et al. 2005). Anterior gradient 2 was also demonstrated to increase
migration and xenograft tumor growth in two esophageal adenocarcinoma cell lines using
both in vitro and in vivo assays (Wang, Hao, and Anson W. Lowe 2008). Another set of
in vitro studies found that silencing of secreted AGR2 is capable of decreasing the ability
of prostate cancer cells to grow, survive, and undergo invasion, suggesting that AGR2
plays a role in these cellular functions in prostate cancer (Ramachandran et al. 2008).
Similarly, another group demonstrated that knockdown of AGR2 expression in cell lines
isolated from ERα-positive breast cancers reduced the ability of the cell lines to grow,
progress through the cell cycle, and undergo anchorage-independent growth (Vanderlaag
et al. 2010). More recent studies have also demonstrated that IGF-1 can induce AGR2
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expression and that exposure to extracellular AGR2 can stimulate increased growth,
migration, and progression through the cell cycle as well as EMT in MCF-7 cells (Li et
al. 2015; Li et al. 2016).
In an attempt to define a reason for the above heterogeneity in AGR2 expression,
AGR2 was determined in CICs isolated as spheroids from the individual cell lines. As
detailed in the results the spheroids fulfill the requirement to be defined as CICs. The
results show that CICs isolated from the As3+ and Cd2+-transformed cell lines all have
expression, be it variable, of AGR2 mRNA. This appears to be one of the first
observations that AGR2 is expressed in CICs isolated from transformed cells in culture.
In addition, the tumors derived from the CICs isolated from two each of the As3+ and
Cd2+-transformed cell lines demonstrated moderate to strong staining of AGR2 in 20 to
30% of the cells. Taken together the findings suggest the following evolution of AGR2
expression from cell culture to tumor transplants. First, the expression of AGR2 mRNA
and protein in the As3+ and Cd2+-transformed cell cultures, while interesting, probably
has very little to do with the subsequent expression of AGR2 in the tumor transplants.
The rationale being that the expression of AGR2 is dictated by the small sub-population
of CICs and not the overall AGR2 signature of the entire culture. In the two previous
studies with CICs from the As3+ and Cd2+-transformed cells, the expression in the tumor
transplant recapitulated the expression in the CICs and not the entire culture (Sandquist et
al. 2016; Slusser-Nore et al. 2016). This suggests that the tumor transplants are initiated
by CICs that express the AGR2 gene. One may also speculate that AGR2 might enhance
tumor initiation since AGR2 expression has been suggested in an analysis of clinical
specimens to assist the local invasion of urothelial cancer cells (Ho et al. 2016).
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Second, the expression pattern of AGR2 in tumor cells within the tumor
transplants would be consistent with AGR2 being present at the early stages of tumor
growth and then becoming dormant as the tumor undergoes differentiation into higher
grade tumor cells. This is suggested by the fact that previous studies have shown tumor
transplants derived from these cell lines undergo squamous differentiation, producing a
tumor with a more undifferentiated cell population and one comprised of cells with
squamous character (Sens et al. 2004; Cao et al. 2010; Somji et al. 2010). Squamous
differentiation in urothelial cancer is associated with a poor prognosis (Logothetis et al.
1989; Martin, Jenkins, and Zuk 1989; Akdaš and Türkeri 1991; Frazier et al. 1993). In
the present study the differentiated squamous components of the tumor transplants were
negative for the expression of AGR2 while the more undifferentiated components stained
positive for AGR2. These observations are consistent with AGR2-expressing CICs
initiating the tumor transplant, undergoing initial proliferation to form the tumor, and a
loss of AGR2 as the tumor differentiates/progresses to a higher grade, more aggressive
cell type. What the study does not answer is if the undifferentiated AGR2 staining
component is driving continued tumor growth or if the AGR2 positive cells would
disappear from the tumor if growth was continued by serial passage. Overall, the results
show that CICs derived from the UROtsa model system provide are useful in helping to
define the role of AGR2 expression from tumor initiation through serial transplant of the
tumor, which could eventually further the study of tumor initiation and metastasis to
other organ sites.
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4.2 AGR2 in the Breast
Breast cancer has become a focus for cancer research and represents one of the
greatest health concerns for women in developed countries. One area of breast cancer
research warranting further study is the significance of AGR2 expression in the breast.
Even with recent advances, there remains a need to discover more accurate and
informative biomarkers for breast cancers, not only to aid in early detection but to allow
for more informed treatment decisions based on biomarkers which might more accurately
predict a given patient’s prognosis. Previously this lab has observed that the protooncogene AGR2 exhibits increased expression following As3+ or Cd2+-transformation of
UROtsa cells, based on microarray analysis (Garrett et al. 2014). This prompted the
further evaluation and characterization of AGR2 expression in a model of As3+ and Cd2+induced breast cancers which was created using the MCF-10A breast epithelial cell line.
Preliminary experiments demonstrated that AGR2 expression increases following
transformation of MCF-10A cells with As3+ and that AGR2 expression is induced by
exposure to As3+ in MCF-10A cells. These results add to previous studies linking As3+
exposure to breast cancer risk (Xu, Erik J Tokar, and Waalkes 2014).
A possible connection of AGR2 expression to ERα status is also of interest as
AGR2 expression has previously been shown to be responsive to the presence of estrogen
and ERα (Thompson and Weigel 1998; Innes et al. 2006; Salmans, Zhao, and Andersen
2013). For example, it has been previously established that AGR2 expression predicts
poor prognosis when highly expressed in ERα-positive breast cancers (Barraclough et al.
2009; Hrstka et al. 2010; Lacambra et al. 2015). Other experiments have also indicated
that AGR2 exhibits expression and functions that are independent of ERα status, though
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this area has not been well studied (Hrstka et al. 2010). In this study, AGR2 expression
was demonstrated in the ERα-positive T47D and MCF-7 cell lines and in the ERαnegative MDAMB cell line, indicating that AGR2 expression is common in some
subtypes of breast cancers. In this study it was further demonstrated that ERα is not
highly expressed in the MCF-10A cell lines, showing that As3+ and Cd2+-transformed
MCF-10A cells remained ERα-negative. This suggests that any effect seen as a result of
AGR2 expression in transformed MCF-10A cells may be due to ERα-independent
mechanisms or functions. This also suggests an explanation for why AGR2 functions and
responses in the MCF-10A model may differ from what has been previously
demonstrated in literature involving AGR2.
Anterior gradient 2 expression has previously been known to impact cell
functions with potential to contribute to both tumorigenesis and to the progression of
cancers, particularly metastasis (Liu et al. 2005; Wang, Hao, and Anson W. Lowe 2008;
Park et al. 2011; Tsuji et al. 2014; Li et al. 2015; Fessart et al. 2016; Li et al. 2016). In
breast and other cancers, AGR2 expression has also been shown to enable cancer
progression and tumor cell survival (Vanderlaag et al. 2010; Dumartin et al. 2011;
Brychtova et al. 2014). Here this study has demonstrated that As3+-transformation is
capable of increasing cell growth and migration in MCF-10A cells, suggesting that As3+
exposure can lead to cellular responses which may result in tumorigenesis or metastasis.
While not fully established in this study, data suggest the possibility that the mechanism
by which this process occurs could involve the induction of AGR2 expression as this
study demonstrated the ability of As3+ to induce AGR2 expression. In this study, it was
shown that AGR2 overexpression itself can induce cell proliferation and motility in

86

MCF-10A cells transfected with the AGR2 gene. This suggests a role for AGR2 in
conferring properties to breast epithelia which have been known to contribute to tumor
formation, progression, and metastasis (Wang, Hao, and Anson W. Lowe 2008; Di Maro
et al. 2014). In short, the induction of AGR2 expression, by As3+ among other means,
may stimulate growth in breast epithelia resulting in tumor formation and eventual
metastasis.
The present study has demonstrated that AGR2 is localized mainly to the
endoplasmic reticulum in the MCF-10A cell lines, which is consistent with the previously
established AGR2 role as a PDI in breast epithelia. Functioning as a PDI, responding to
endoplasmic reticulum stress, is the most well-understood role which has been
established so far for AGR2 in previous studies (Higa et al. 2011). As part of its ability to
function as a PDI, it has been shown that AGR2 can be secreted when the KTEL
endoplasmic reticulum retention sequence is lost (Park et al. 2009; Gupta, Dong, and
Lowe 2012; Bergström et al. 2014). This prompted the determination of whether or not
AGR2 is being secreted in the MCF-10A model. Data revealed that AGR2 is not secreted
by MCF-10A cells, even when AGR2 expression is increased due to As3+-transformation
or AGR2 transfection into the cell. These data further suggest that AGR2 is primarily
functioning within the endoplasmic reticulum in MCF-10A cells.
Previous work has established that AGR2 expression is a predictor of poor
prognosis in breast cancers and is associated mainly with more advanced breast cancers
(Fritzsche et al. 2006; Barraclough et al. 2009; Hrstka et al. 2010). Evaluation of AGR2
expression in breast carcinoma specimens of low and high grade DCISs and grade 1, 2,
and 3 IDCs demonstrated that AGR2 expression correlates to tumor grade with the
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strongest staining seen in the higher grades of IDC. This strengthens the data supporting
AGR2 expression as a useful biomarker for advanced breast cancers.
Little is known regarding the mechanisms that regulate AGR2 expression at this
time. If the regulation of AGR2 were better understood, it could lead to potential targets
for future cancer therapies aimed at inhibiting the progression or metastasis of AGR2
expressing cancers. As this project has demonstrated that As3+ exposure can induce
AGR2 expression in MCF-10A cells, a potential mechanism by which AGR2 expression
is regulated was evaluated. One potential regulatory mechanism for gene expression that
has been previously associated with AGR2 expression involves DNA methylation (Sung
et al. 2014). Another common mechanism for the epigenetic regulation of gene
expression involves histone acetylation (Struhl 1998). After evaluating AGR2 expression
in response to a HDAC inhibitor (MS-275) and an inhibitor of DNA methylation (5AZC), data reveal that AGR2 expression in MCF-10A cells is regulated, at least partially,
by these epigenetic mechanisms.
From this study, a picture begins to form which allows for an improved level of
understanding regarding AGR2 expression and regulation, particularly in relation to those
functions with the potential to affect cancers of the bladder and breast. It is possible that
As3+ exposure induces AGR2, potentially through epigenetic means such as histone
acetylation and DNA methylation. This induction of AGR2 in turn may stimulate the
formation, proliferation, and eventual migration of affected epithelial cells in the breast or
bladder, among others. This study demonstrates the potential usefulness of further
research aimed at increasing the current understanding of the regulation and involvement
of AGR2 expression in breast and bladder cancers.
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ABBREVIATIONS
5-AZC

5’-azacytidine

AGR2

human Anterior Gradient 2 homolog

AKT

Protein Kinase B

ALDH1

Aldehyde Dehydrogenase 1

ANOVA

Analysis of Variance

AP-1

Activator Protein 1

AREG

Amphiregulin

As3+

Arsenite

ATCC

American Type Culture Collection

ATF6

Activating Transcription Factor 6

BCG

Bacillus Calmette-Guerin

Cd2+

Cadmium

CdCl2

Cadmium Chloride

CDH1

Epithelial-cadherin

CDH2

Neuronal-cadherin

cDNA

Complementary Deoxyribonucleic Acid

CI

Confidence Interval

CICs

Cancer Initiating Cells

CIS

Carcinoma in Situ

CO2

Carbon Dioxide
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DAB

3,3’-diaminobenzidine

DMA

Dimethyl Arsenic

DMEM

Dulbecco’s Modified Eagle Medium

DMT

DNA Methyl-transferase

DNA

Deoxyribonucleic Acid

DTT

Dithiothreitol

EDTA

Ethylenediaminetetraacetic Acid

EGF

Epidermal Growth Factor

EGFR

Epidermal Growth Factor Receptor

EMT

Epithelial to Mesenchymal Transition

ER

Endoplasmic Reticulum

ERα

Estrogen Receptor Alpha

ErbB3

Receptor Tyrosine Protein Kinase erbB-3

ERE

Estrogen Response Element

ERK

Extracellular Signal-related Kinase

ESR1

Estrogen Receptor Alpha

FBS

Fetal Bovine Serum

GSC

Gleason Score

GSH

Glutathione

HDAC

Histone Deacetylase

HER2

Human Epidermal Growth Factor Receptor 2

hrs

Hours

IARC

International Agency for Research on Cancer
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iAs

Inorganic Arsenic

IDC

Infiltrative Ductal Carcinoma

IGF-1

Insulin-like Growth Factor 1

IHC

Immunohistochemistry

I.O.D.

Integrated Optical Density

IRE1

Inositol Requiring 1

MAPK

Mitogen Activated Protein Kinase

MET

Mesenchymal to Epithelial Transition

μl

Microliter

μM

Micromolar

ml

Milliliter

min

Minute

MMA

Monomethyl Arsenic

MRI

Magnetic Resonance Imaging

mRNA

Messenger Ribonucleic Acid

MS-275

Entinostat

mTOR

Mammalian Target of Rapamycin

MTT

Thiazoyl Blue Tetrazodium Bromide

MUC2

Mucin

NaAsO2

Sodium Arsenite

nM

Nanomolar

O.D.

Optical Density
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PBS

Phosphate Buffered Saline

PCR

Polymerase Chain Reaction

PDI

Protein Disulfide Isomerase

PERK

Protein Kinase-Like Endoplasmic Reticulum Kinase

PIN

Prostatic Intraepithelial Neoplasia

PR

Progesterone Receptor

PRK

Protein Kinase

PSA

Prostate Specific Antigen

PVDF

Polyvinylidene Difluoride

RCF

Relative Centrifugal Force

RNA

Ribonucleic Acid

RT-PCR

Real-time Polymerase Chain Reaction

SDS

Sodium Dodecyl Sulfate

SDS-PAGE

Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis

SEM

Standard Error of the Mean

siRNA

Small Interfering Ribonucleic Acid

TURBT

Transurethral Resection of Bladder Tumor

VIM

Vimentin

YAP1

Yes-Associated Protein 1
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